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A B S T R A C T
Background
Clinical trials and observational data have variously shown a protective, harmful or neutral effect of antihypertensives on cognitive
function. In theory, withdrawal of antihypertensives could improve cerebral perfusion and reduce or delay cognitive decline. However,
it is also plausible that withdrawal of antihypertensives may have a detrimental effect on cognition through increased incidence of stroke
or other vascular events.
Objectives
To assess the effects of complete withdrawal of at least one antihypertensive medication on incidence of dementia, cognitive function,
blood pressure and other safety outcomes in cognitively intact and cognitive impaired adults.
Search methods
We searched ALOIS, the specialised register of the Cochrane Dementia and Cognitive Improvement Group, with additional searches
conducted in MEDLINE, Embase, PsycINFO, CINAHL, LILACS, Web of Science Core Collection, ClinicalTrials.gov and theWorld
Health Organization Portal/ICTRP on 12 December 2015. There were no language or date restrictions applied to the electronic
searches, and no methodological filters were used to restrict the search.
Selection criteria
We included randomised controlled trials (RCTs) and controlled clinical trials (CCTs) provided they compared withdrawal of anti-
hypertensive medications with continuation of the medications and included an outcome measure assessing cognitive function or a
clinical diagnosis of dementia. We included studies with healthy participants, but we also included studies with participants with all
grades of severity of existing dementia or cognitive impairment.
Data collection and analysis
Two review authors examined titles and abstracts of citations identified by the search for eligibility, retrieving full texts where needed
to identify studies for inclusion, with any disagreement resolved by involvement of a third author. Data were extracted independently
on primary and secondary outcomes. We used standard methodological procedures expected by Cochrane.
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The primary outcome measures of interest were changes in global and specific cognitive function and incidence of dementia; secondary
outcomes included change in systolic and diastolic blood pressure, mortality, adverse events (including cardiovascular events, hospital-
isation and falls) and adherence to withdrawal. The quality of the evidence was evaluated using the GRADE approach.
Main results
We included two RCTs investigating withdrawal of antihypertensives in 2490 participants. There was substantial clinical heterogeneity
between the included studies, therefore we did not combine data for our primary outcome. Overall, the quality of included studies was
high and the risk of bias was low. Neither study investigated incident dementia.
One study assessed withholding previously prescribed antihypertensive drugs for seven days following acute stroke. Cognition was
assessed using telephone Mini-Mental State Examination (t-MMSE) and Telephone Interview for Cognitive Status (TICS-M) at 90
days as a secondary outcome. The t-MMSE score was a mean of 1.0 point higher in participants who withdrew antihypertensive
medications compared to participants who continued them (95% confidence interval (CI) 0.35 to 1.65; 1784 participants) and the
TICS-M was a mean of 2.10 points higher (95% CI 0.69 to 3.51; 1784 participants). However, in both cases the evidence was of
very low quality downgraded due to risk of bias, indirectness and evidence from a single study. The other study was community based
and included participants with mild cognitive impairment. Drug withdrawal was for 16 weeks. Cognitive performance was assessed
using a composite of at least five out of six cognitive tests. There was no evidence of a difference comparing participants who withdrew
antihypertensive medications and participants who continued (mean difference 0.02 points, 95% CI -0.19 to 0.21; 351 participants).
This evidence was of low quality and was downgraded due to risk of bias and evidence from single study.
In one study, the systolic blood pressure after seven days of withdrawal was 9.5 mmHg higher in the intervention compared to the
control group (95% CI 7.43 to 11.57; 2095 participants) and diastolic blood pressure was 5.1 mmHg higher (95% CI 3.86 to 6.34;
2095 participants). This evidence was low quality, downgraded due to indirectness, because the data must be interpreted in the context
of the wider study looking at glyceryl trinitrate administration or not, and evidence from a single study. In the other study, systolic blood
pressure increased by 7.4 mmHg in the withdrawal group compared to the control group (95% CI 7.08 to 7.72; 356 participants)
and diastolic blood pressure increased by 2.6 mmHg (95% CI 2.42 to 2.78; 356 participants). This was moderate quality evidence,
downgraded as evidence was from a single study.We combined data for mortality and cardiovascular events. There was no clear evidence
that antihypertensive medication withdrawal affected adverse events, although there was a possible trend to increased cardiovascular
events in the large post-stroke study (pooled mortality risk ratio 0.88, 95% CI 0.72 to 1.08; 2485 participants; and cardiovascular
events risk ratio 1.29, 95% CI 0.96 to 1.72). Certain prespecified outcomes of interest (falls, hospitalisation) were not reported.
Authors’ conclusions
The effects of withdrawing antihypertensive medications on cognition or prevention of dementia are uncertain. There was a signal
of a positive effect in one study looking at withdrawal after acute stroke but these results are unlikely to be generalisable to non-
stroke settings and were not a primary outcome of the study. Withdrawing antihypertensive drugs was associated with increased blood
pressure. It is unlikely to increase mortality at three to four months’ follow-up, although there was a signal from one large study looking
at withdrawal after stroke that withdrawal was associated an increase in cardiovascular events.
P L A I N L A N G U A G E S U M M A R Y
Antihypertensive withdrawal for the prevention of cognitive decline
Background
Dementia and cognitive impairment are a global health concern which place a burden on patients and carers, and increase healthcare
costs. Therefore, it is important to identify ways to prevent their occurrence. Previous research has suggested that withdrawal (stopping)
of blood pressure loweringmedicines might increase the blood flow to the brain and therefore prevent problems of memory and thinking
in older age. In this review, we included clinical studies comparing the effects on memory and thinking of withdrawal of blood pressure
lowering medicines versus continuation of these medicines.
Included studies
We found two relevant studies with 2490 participants. The two studies differed in a number of ways. One of the studies withdrew
medicine for seven days immediately after a stroke, the other withdrew medicine for three months in older adults with early memory
problems.
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Results
The two studies did not report new cases of dementia, rather they described performance on standardised tests of memory and thinking.
The older-adult study did not find a difference between the participants who stopped and participants who continued medicine. The
stroke study found better test scores in participants who stopped medicine, but this must be interpreted with caution since this was
measured in such a specific patient population. As expected, blood pressure rose in both studies in the groups that stopped their blood
pressure lowering medicines, but there was no short-term increase in heart attacks, strokes or death.
Conclusion
At present, there is not enough evidence to prove or disprove effects of stopping blood pressure medicines on memory and thinking.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antihypertensive withdrawal for the prevention of cognitive decline
Patient or population: adults with cognit ive impairment/ dementia and cognit ively intact populat ions
Setting: any sett ing
Intervention: ant ihypertensive withdrawal for the prevent ion of cognit ive decline
Comparison: ant ihypertensive cont inuat ion
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with antihyperten-
sive continuation
Risk with antihyperten-
sive withdrawal
Incident dementia - not
measured
n/ a n/ a Not est imable - - -
Cognit ion (at 90 days):
t-MMSE score1
The mean t-MMSE
score was 9
The mean t-MMSE
score in the interven-
t ion group was 1 point
higher (0.35 to 1.65
points higher)
- 17842
(1 RCT)
Bath 2015
⊕©©©
very low3,4,5
Lower scores indi-
cate worse cogni-
t ive funct ioning. Part ic-
ipants with acute stroke
af ter 7 days of ant ihy-
pertensive withdrawal
Composite cognit ive
funct ion6 (change over
16 weeks)
The mean change in
cognit ive funct ion was
0.01 points lower
The mean change in
cognit ive funct ion in
the intervent ion group
was 0.02 points higher
(0.19 lower to 0.23
points higher)
- 3517
(1 RCT)
Moonen 2015
⊕⊕©©
low3,5
Lower total scores in-
dicate worse cogni-
t ive funct ioning. Part ic-
ipants with MCI
Mortality (at 3 to 4
months’ follow-up)
Study populat ion RR 0.88
(0.72 to 1.08)
2485
(2 RCTs)
⊕⊕⊕©
moderate4
-
118 per 1000 104 per 1000
(85 to 128)
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Cardiovascular events
(at 3 to 4 months’ fol-
low-up)
Study populat ion RR 1.29
(0.96 to 1.72)
2485
(2 RCTs)
⊕⊕©©
low4,8
-
61 per 1000 79 per 1000
(59 to 105)
Falls - not measured n/ a n/ a Not est imable - - -
Hospitalisat ions (at 4
months’ follow-up)
Study populat ion RR 0.85
(0.36 to 2.06)
388
(1 RCT)
Moonen 2015
⊕⊕©©
low5,8
-
53 per 1,000 45 per 1,000
(19 to 109)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; MCI: mild cognit ive impairment; n/a: not available; RR: risk rat io; t-MMSE: telephone Mini-Mental State Examinat ion.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Telephone Mini-Mental State Examinat ion Score range 0 to 22 points.
2Based on number alive at 90 days; data not available by group on number assessed.
3Downgraded due to risk of performance bias arising f rom part icipants and personnel not being blinded.
4Downgraded due to indirectness as majority of study part icipants were people with acute stroke.
5Downgraded as evidence f rom single study.
6Compound overall cognit ive score presented. Included components were: t ime to complete Trail Making Test parts A and B;
Interference score of the abbreviated Stroop Color-Word Test; Immediate and Delayed Recall on the 15-word verbal learning
test; Visual Associat ion Test and Letter Digit Subst itut ion Test. Compound scores were computed by convert ing the raw
scores of each test to standardised z scores ((test score - mean)/ standard deviat ion) and calculat ing the mean z scores
across the tests in each compound.
7Data missing for three in the intervent ion and two in the control group.
8Downgraded due to imprecision.
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B A C K G R O U N D
Hypertension (blood pressure above a recommended value) is a
common clinical condition with a well-established causal role in
cardiovascular disease (Lewington 2002). Hypertension is partic-
ularly prevalent in older age; more than half of the population
over the age of 50 years, and approximately 80% of the popula-
tion older than 80 years have hypertension (Chow 2013; Cohen
2011). The protective effect of antihypertensive treatment against
cardiovascular events and premature mortality is well established
(Law 2009; Musini 2009). The evidence to support treatment of
hypertension in healthy older adults is robust (Beckett 2012). Ev-
idence for benefit of antihypertensive therapy in frail older adults
with comorbidities and geriatric syndromes including cognitive
and functional decline is limited, and some data suggest potential
for harm, with studies describing association between antihyper-
tensive therapy and higher mortality (Benetos 2015a), and serious
injuries arising from falls (Tinetti 2014).
The evidence for antihypertensive therapy in people with cognitive
impairment or dementia, and the impact of this treatment on cog-
nition is uncertain, with conflicting results in published data and
no meta-analysis possible due to heterogeneity (Beishon 2014).
Data have variously shown a protective, harmful or neutral effect
of antihypertensives on cognition. One study with almost 5000
older adults, suggested no detrimental effect of antihypertensive
treatment on cognitive function in people with existing cognitive
problems (Skoog 2005). Two other large studies did not show a
reduction of incident dementia in people treated with antihyper-
tensive medications (Di Bari 2001; Peters 2008). However, other
work suggested a protective effect of antihypertensive treatment on
vascular-induced dementia (Tzourio 2003), while another study
reported potential for antihypertensive medication to accelerate
cognitive decline (Alrawi 2013).
These seemingly conflicting trial data may be explained by the
complex relationship between blood pressure and cognition over
the life course. Hypertension in middle-age is a risk factor for in-
cident dementia, driven at least in part by cerebrovascular disease
(Norton 2014). However, the association between blood pressure
and dementia at an older age is inverse (Kennelly 2009;Qiu 2009).
Several years before dementia onset, a decrease in blood pressure
canbe seen (Skoog 1996), and lowbloodpressure is associatedwith
cognitive decline in the years after diagnosis (Nilsson 2007), al-
though the direction of causality is unknown. Several mechanisms
were proposed to underlie this decrease in blood pressure in the
years before the diagnosis of dementia, including autonomic dys-
regulation as symptom of neurodegeneration (den Abeelen 2014).
The arteriosclerotic and age-related changes to cerebral blood flow
autoregulation in older people could also result in cerebral hy-
poperfusion, potentially influencing cognitive functioning (Qiu
2009).
Thus, the evidence base for cognitive benefits of hypertension
treatment in midlife is compelling, but the evidence for cognitive
effects of hypertension treatment in older age is less clear. The
Cochrane systematic review on hypertension treatment in elderly
people showed that adherence to treatment is limited and a con-
siderable proportion of older people discontinue treatment, due
to adverse effects, in particular when the level of prescribed treat-
ment increased (Musini 2009). Taking all this into account, there
is a concern that antihypertensive medication may have potential
for harm in people with cognitive impairment/dementia and it
may negatively influence cognitive functioning. There is an associ-
ated debate regarding the benefit of withdrawing antihypertensive
therapy in older adults, since the risk-benefit ratio of treatment
might be different at differing ages and with different classes of
antihypertensive medications (Shah 2009).
It would be interesting for patients, carers and policymakers if
withdrawal of antihypertensive medications has a positive effect
on cognitive functioning, since this might possibly lead to a de-
crease in dementia incidence and thus major health cost savings.
Reducing medication use will also contribute to less healthcare
expenditures. Such withdrawal may take place in isolation, or may
be part of a wider medication review or deprescribing exercise. De-
prescribing is “the process of tapering or stopping drugs, aimed at
minimizing polypharmacy and improving patient outcome” and
is a growing area with observation and trial evidence (Scott 2015).
Older adults (Opondo 2012), care home residents (Stafford 2011),
and people with advanced dementia (Tjia 2014) are all popula-
tions in whom inappropriate prescribing is thought to be common
with scope for improvements through deprescribing or electronic
systems for medication review.
The purpose of this systematic review was to summarise all avail-
able evidence on cognitive effects of withdrawal of antihyperten-
sive medications and associated benefits and harms in adults (in-
cluding healthy adults and people with prevalent cognitive de-
cline).
Description of the condition
We have focused on the implications of antihypertensive medica-
tion on cognitive functioning, including cognitive decline and de-
mentia.Cognitive decline is often accompanied by deterioration in
emotional control, social behaviour ormotivation. The number of
people living with cognitive impairment not classified as dementia
is probably even higher, but no exact data on this exist. The term
’mild cognitive impairment’ (MCI) refers to a ’syndrome defined
as cognitive decline greater than expected for an individual’s age
and education level but that does not interfere notably with activ-
ities of daily life’ (Gauthier 2006). Although rates of conversion
from MCI to dementia vary, it is thought that people with MCI
are at an increased risk of developing dementia (Bruscoli 2004).
The term ’dementia’ refers to a group of diseases which shares a
syndrome that is typically chronic and progressive in nature. The
dementia syndrome involves disturbances of multiple higher cor-
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tical functions, such as memory, thinking, orientation, perception
and behaviour, which are severe enough to affect the ability to
perform everyday activities. Although the incidence of dementia
is thought to be declining inWestern countries (Matthews 2016),
the prevalence is increasing due to the ageing world population
meaning larger numbers of people are living with dementia (Ferri
2005). Worldwide, 47.5 million people were estimated to be af-
fected in 2015 and it is anticipated that this figure will double by
2030, resulting in high costs and considerable burden to individ-
uals and societies (WHO 2015).
Description of the intervention
In this review, we identified and appraised randomised controlled
trials (RCTs) and controlled clinical trials (CCTs) which evalu-
ated the cognitive consequences of withdrawal of antihypertensive
treatment in adults. For this review, we defined ’antihypertensive
treatment’ as the use of any drug with any blood pressure lowering
effect, prescribed for any indication.
Major classes of antihypertensive drugs include thiazide diuretics,
beta-blockers, drugs inhibiting the renin-angiotensin system, cal-
cium channel blockers, direct vasodilators, centrally active drugs
and others. The different classes of antihypertensive drugs have
differential effects on some outcomes, and it is possible that they
have differential effects on cognition. Some studies have suggested
that especially calcium channel blockers (Yasar 2005) and diuret-
ics (Khachaturian 2006; Qui 2003) may have a protective effect
on cognition, but this has not been shown in a RCT.
How the intervention might work
There are plausible theoretical reasons why withdrawal of anti-
hypertensive therapy may have a beneficial effect on cognition.
One of these reasons might be autonomic dysregulation as symp-
tom of neurodegeneration (den Abeelen 2014). Another theory
is about arteriosclerotic and age-related changes to cerebral blood
flow autoregulation in older adults, resulting in cerebral hypop-
erfusion (Qiu 2009) and potentially influencing cognitive func-
tioning. Equally, withdrawal of antihypertensive therapy may ac-
celerate cognitive decline through incident stroke or progression
of small vessel disease.
Interventions to completely withdraw at least one antihypertensive
medication in people with and without cognitive problems may
also reduce adverse effects and improve quality of life for the patient
and carer. However, they may also cause withdrawal symptoms
such as ’rebound’ tachycardia with withdrawal of beta-blocker,
headache, agitation and nausea (Karachalios 2005). Therefore, we
have examined trials which evaluate effects of antihypertensive
withdrawal, contributing to the evidence base in this area.
Why it is important to do this review
Contemporary guidelines for blood pressure management in older
adults focused on indications for treatment and choice of treat-
ment. It is possible that withdrawal of antihypertensive medica-
tion in certain older-adult populations may have beneficial effects
on cognition or rates of incident dementia, or both. A cost saving
intervention (drug withdrawal) that impacts on cognition would
have important individual and public health implications. Drug
withdrawal might also decrease the burden of polypharmacy. This
burden is usually accompanied with minor and major adverse
events, so withdrawal of drugs may have a positive impact. A syn-
thesis of all relevant data moves us closer to adopting evidence-
based interventions, or identifies the evidence gaps that require
further original research. In general, studies that address the effect
of withdrawal of drugs in adult populations are highly relevant
to prevent unnecessary and potentially harmful treatments. It is
recognised that the initiation and continuation of inappropriate
medications is known to negatively impact on the safety of pa-
tients (Anathhanam 2012), thus medication withdrawal has the
potential to improve safety, provided it does not come with ad-
ditional greater risks. Finally, improved understanding of medi-
cation withdrawal is of particular interest to patients who should
be active participants in any deprescribing process. Exploring and
addressing their concerns and understanding is critical in success-
ful withdrawal (Reeve 2013), and improving the evidence base
behind recommendations is a key component of this.
O B J E C T I V E S
To assess the effects of complete withdrawal of at least one antihy-
pertensive medication on incidence of dementia, cognitive func-
tion, blood pressure and other safety outcomes in cognitively in-
tact and cognitive impaired adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We selected studies if they met the following criteria: RCTs com-
paring withdrawal of antihypertensive medications with continu-
ation of the medications. We also included CCTs that meet other
inclusion criteria. An outcome measure assessing cognitive func-
tion or dementia diagnosis had to be clearly defined.
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Types of participants
Participants were aged 18 years and over. Participants must have
been taking the antihypertensive medications for a minimum of
one month irrespective of indication.
Participants could reside in any healthcare setting (including acute
hospitals, nursing and residential homes, and the community).
We included healthy participants and participants with all grades
of severity of existing dementia or cognitive impairment.
Types of interventions
Withdrawal of anymedicationwith bloodpressure lowering effects
(see list of relevant medications included in Appendix 1) with no
restriction to duration of follow-up.
Types of outcome measures
Primary outcomes
• Cognitive impairment or rates of incident dementia in
cognitively intact and cognitively impaired adults.
• Cognition in the short-term in adults with or without
established cognitive impairment.
Cognitive function quantified with a recognised assessment in-
strument including multiple cognitive domains, for example
(but not limited to) Folstein’s Mini Mental State Examina-
tion (MMSE) (Folstein 1975), Montreal Cognitive Assessment
(MoCA) (Nasreddine 2005), more extensive neuropsychological
testing, or formal clinical diagnosis of dementia according to cur-
rent internationally accepted guidelines, for example (but not
limited to) International Classification of Diseases and Related
Health Problems (ICD-10) andDiagnostic and Statistical Manual
of Mental Disorders (DSM-IV).
Secondary outcomes
• Changes in systolic and diastolic blood pressure.
• Rates of (serious) adverse events across the included studies.
These included mortality, cardiovascular events, early (within
first eight weeks) and late (post-six months) adverse effects (e.g.
falls and hospitalisation).
• Adherence to withdrawal of the antihypertensive
medications. We defined adherence to withdrawal as participants
remaining off medication for the duration of the study or at least
six months, whichever was longer.
Search methods for identification of studies
We used the electronic databases listed below to search for relevant
studies regardless of language, personnel, research setting or date
of publication.
Electronic searches
We searched ALOIS (www.medicine.ox.ac.uk/alois) - the
Cochrane Dementia and Cognitive Improvement Group’s (CD-
CIG) specialised register on 12 December 2015.
ALOIS is maintained by the Trials Search Co-ordinator for the
CDCIG, and contains studies that fall within the areas of dementia
prevention, dementia treatment and management, and cognitive
enhancement in healthy older adult populations. The studies are
identified through:
• monthly searches of a number of major healthcare
databases: MEDLINE, Embase, CINAHL, PsycINFO and
LILACS;
• monthly searches of a number of trial registers: ISRCTN;
UMIN (Japan’s Trial Register); the World Health Organization
(WHO) portal (which covers ClinicalTrials.gov; ISRCTN; the
Chinese Clinical Trials Register; the German Clinical Trials
Register; the Iranian Registry of Clinical Trials and the
Netherlands National Trials Register, plus others);
• quarterly search of the Cochrane Central Register of
Controlled Trials (CENTRAL); and
• six-monthly searches of a number of grey literature sources:
ISI Web of Knowledge Conference Proceedings; Index to Theses
and Australasian Digital Theses.
To view a list of all sources searched for ALOIS see AboutALOIS
on the ALOIS website (www.medicine.ox.ac.uk/alois).
Details of the search strategies run in healthcare bibliographic
databases, used for the retrieval of reports of dementia, cognitive
improvement and cognitive enhancement trials, can be viewed in
the ’Methods used in reviews’ section within the editorial informa-
tion about the Cochrane Dementia and Cognitive Improvement
Group.
We ran additional searches
in MEDLINE, Embase, PsycINFO, CINAHL, LILACS, Web of
Science core collection, ClinicalTrials.gov and the WHO Portal/
ICTRP to ensure that the search was as comprehensive and up-
to-date as possible. See Appendix 2 for the search strategy that we
used to retrieve reports of trials fromMEDLINE (via the OvidSP
platform).
Searching other resources
In case of incomplete reports or conference abstracts, we con-
ducted further searches for connected papers and, if necessary, we
contacted authors to obtain missing information.
We handsearched the reference lists of the relevant articles that
we retrieved and searched for non-MEDLINE listed journals. We
also searched the Science Citation Index for articles citing key
references. We emailed two North American research groups with
active deprescribing research programmes to check we had not
missed any relevant studies.
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Data collection and analysis
Selection of studies
Phase 1: two review authors (SJ and JH) independently performed
searches and screening of identified studies. We independently ex-
amined titles and abstracts of citations obtained from the searches
and discarded obviously irrelevant articles. At this stage, we were
overly inclusive; we retrieved for further assessment any article that
suggested a relevant study.
Phase 2: from the potentially relevant articles in Phase 1, two
review authors (SJ and JH) independently selected studies (based
on the full-text format) for inclusion. We resolved disagreement
on study inclusion by consensus or third party adjudication (ER).
We detailed the study selection process in a PRISMA flow diagram
(Moher 2009; Figure 1).
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Figure 1. PRISMA Study flow diagram.
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Data extraction and management
Two review authors (SJ and JH) independently performed data
extraction using a prespecified data extraction form and entered
the data into Review Manager 5 software (RevMan 2014). In case
of discrepancies, we involved a third review author (ER) until we
reached consensus.
We created and used a specific data extraction form, includ-
ing source, methods, participants, interventions, outcomes, re-
sults, funding source and declarations of interest according to the
Cochrane Handbook for Systematic Reviews of Interventions guid-
ance (Higgins 2011).
One review author (SJ) entered the data into Review Manager 5,
which were checked for accuracy by a second review author (JH)
(RevMan 2014).
Assessment of risk of bias in included studies
Two review authors (SJ and JH) independently assessed the inter-
nal validity of each included study. We described the risk of bias
of all included studies in the Characteristics of included studies
table and narrative. We used the Cochrane ’Risk of bias’ tool for
assessment and we used seven standard criteria: random sequence
generation; allocation concealment; blinding of participants and
personnel; blinding of outcome assessment; incomplete outcome
data; selective reporting and other risk of bias (Higgins 2011). We
assessed every study for each of the seven criteria and reported the
information in a ’Risk of bias’ table in Figure 2.
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Figure 2. Cochrane ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for
each included study.
Measures of treatment effect
We used mean differences (MD) or standardised mean differences
(SMD) with 95% confidence intervals (CI) for continuous out-
comes, and risk ratios (RR) with 95% CIs for the analysis of di-
chotomous outcomes.
Scales that are commonly used in dementia trials are often coded
ordinally. We treated the data measured with scales comprising
of more than 10 categories as continuous variables assuming a
normal distribution.
Unit of analysis issues
The unit of analysis was the person undergoing the withdrawal
of an antihypertensive treatment. As defined in our protocol, we
considered for each study whether groups of individuals were ran-
domised together to the same intervention (i.e. cluster-randomised
trials), whether individuals underwent more than one interven-
tion (e.g. in a cross-over trial) or whether there were multiple ob-
servations for the same outcome (e.g. repeated measurements, re-
curring events).
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Dealing with missing data
For each outcome measure, we sought data on every participant
assessed. To allow an intention-to-treat analysis, we sought the
data irrespective of compliance, whether the participant was subse-
quently deemed ineligible, or otherwise excluded from treatment
or follow-up. We did not use data from titration phases prior to
the randomised phase to assess safety or efficacy. We made a qual-
itative judgement as to whether to exclude studies if the impact of
missing data was too large.
Assessment of heterogeneity
We considered clinical heterogeneity between trials (participants,
interventions and outcomes) when deciding whether to synthesise
data. Statistical heterogeneity was considered by using the I2 test
(Higgins 2011). We considered heterogeneity of 30% to 60%
as moderate, 50% to 90% as substantial and 75% to 100% as
considerable. We made a decision on the appropriateness of meta-
analysis based on statistical and clinical heterogeneity.
Assessment of reporting biases
We searched for non-published as well as published studies in
databases and trial registries, to avoid publication bias. To avoid
language bias, we did not employ language restrictions for included
studies. Where there are multiple publications from one study,
we only included the primary publication to address duplicate
publication bias.
Data synthesis
We decided on suitability of meta-analysis for each outcome by
a qualitative assessment (including statistical and clinical hetero-
geneity) of the included studies.
We conducted data synthesis and analyses using Review Manager
5 software (RevMan 2014).We planned to use RRs and a random-
effectsmodel to combine outcomes across trials for ameta-analysis.
The weighting factor for each study would be the inverse of the
within-study variance plus a between-study variance component.
Subgroup analysis and investigation of heterogeneity
If we had identified 10 or more trials that contributed to the analy-
ses of primary outcomes, we planned to perform stratified analyses
of the primary effectiveness outcome according to the following
trial characteristics: presence versus absence of dementia or cog-
nitive impairment at baseline, age and type/class of antihyperten-
sive treatment (thiazide diuretics, angiotensin converting enzyme
inhibitors (ACE-I), etc.).
Data presentation - ’Summary of findings’ tables
We used the GRADE approach to assess the quality of the
supporting evidence behind each estimate of treatment effect
(Schünemann 2011a; Schünemann 2011b). We presented key
findings of the review including a summary of the amount of
data, the magnitude of the effect size and the overall quality
of the evidence, in a ’Summary of findings’ table, created using
GRADEproGDT software (GRADEproGDT 2015). We prese-
lected the following outcomes: cognitive impairment (incident de-
mentia (clinical diagnosis) and change in a validated cognitive test
score); change in systolic and diastolic blood pressure; mortality;
cardiovascular events; falls; hospitalisation and adherence to with-
drawal. Following guidance from the CDCIG editorial team, we
decided to exclude change in systolic and diastolic blood pressure
and adherence to withdrawal outcomes from presentation in the
table.
Sensitivity analysis
We planned to perform a sensitivity analysis for pooled results
based on methodological quality. We also planned to perform
sensitivity analyseswithoutCCTs (if identified) to look at the effect
of these studies and to avoid risk of bias from the non-randomised
design. These sensitivity analyses could not be performed due to
the inclusion of only two studies, so there was not enough data to
pool.
R E S U L T S
Description of studies
Results of the search
The electronic searches performed on 12December 2015 retrieved
10,989 results. After initial de-duplication two review authors (SJ
and JH) independently assessed the remaining 10,970 references
for relevance. We received no information for further published
or unpublished studies from experts or manufacturers. We ex-
cluded 10,894 references that were not relevant on title and ab-
stract screening. Two review authors (SJ and JH) independently
assessed 76 full-text articles and conference abstracts for eligibility.
Seventy-three articles did not meet our inclusion criteria and were
excluded. We included three articles referring to two trials (Bath
2015; Moonen 2015). The selection process is summarised in the
PRISMA diagram (Figure 1).
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Included studies
We identified two trials for inclusion with 2490 randomised par-
ticipants (Bath 2015; Moonen 2015). Bath 2015 is known as the
’Efficacy of nitric oxide, with or without continuing antihyper-
tensive treatment, for the management of high blood pressure in
stroke (ENOS) study’.Moonen 2015 is known as the ’Discontinu-
ation of antihypertensive treatment in elderly people on cognitive
functioning (DANTE) study’. In addition to the Characteristics
of included studies table, we reported additional information on
the included studies in Table 1. We did not contact the authors of
either of the included studies since this was not deemed necessary.
Participants
The ENOS study randomised 4011 participants, although only
2097 participants were included in the antihypertensive with-
drawal substudy, as the remainder were not taking antihyperten-
sive medication before admission (Bath 2015). Participants who
were included in the antihypertensive withdrawal substudy had a
more severe phenotype than those who were not taking antihyper-
tensive drugs before randomisation; they were older, more likely
to be women, had higher rates of vascular risk factors and were
less likely to have a normal premorbid Rankin Scale score. The
DANTE study randomised 393 participants (Moonen 2015).
The populations recruited into the two studies were clinically dis-
tinct. In Bath 2015, all participants had to have experienced an
acute stroke, while in Moonen 2015, all participants had MCI
(defined as an MMSE score between 21 and 27) and taking anti-
hypertensive medications.
The mean age of participants in the DANTE study was 81 years
(Moonen 2015), in comparison with 73 years in the ENOS study
(Bath 2015). Moonen 2015 only included people aged 75 years
and older. Men were 39% to 42% of the study population in
DANTE in comparison with 50% to 52% of the study population
in ENOS.
Both studies reported comorbidities at baseline and these seemed
comparable between intervention and control groups (Bath 2015;
Moonen 2015).
Systolic blood pressure was higher at baseline in the ENOS study
at 166 mmHg to 168 mmHg (Bath 2015) in comparison to 147
mmHg to 148 mmHg in the DANTE study, whose eligibility
criteria limited systolic blood pressure to 160 mmHg (Moonen
2015).
Moonen 2015 assessed cognitive status at baseline and follow-
up, while in Bath 2015, cognitive status was unknown at baseline
and only evaluated at follow-up. One study excluded people with
dementia (Moonen 2015).
Only one study reported level of education at baseline, which was
comparable between groups (Moonen 2015).
Both studies included participants taking any classes of antihyper-
tensive treatment. Most participants in both studies were taking
more than two antihypertensive medications, more than 60% of
participants in DANTE (Moonen 2015) and more than 50% of
participants in ENOS (Bath 2015). Diuretic use was higher in
DANTE (54%) than ENOS (16%) and ACE-I use was lower in
DANTE (35%) than ENOS (48%).
Setting
The two clinical settings also varied. Bath 2015 was a large inter-
national multicentre study conducted in acute hospital settings,
recruiting participants at hospital admission.More than 60%were
recruited in the UK, with the remainder worldwide (Bath 2015).
Moonen 2015 was conducted in primary care in the Leiden region
of the Netherlands, with participants recruited by general practi-
tioners (GPs).
Interventions and comparators
The interventions reported in each of the studies vary in duration
of antihypertensive withdrawal from seven days (Bath 2015) to
three months (Moonen 2015).
Bath 2015 was a parallel-group design RCT with four groups.
The entire sample was randomised to receive a glyceryl trinitrate
(GTN) patch (intervention) or no patch (control). All participants
who were taking antihypertensive medications prior to admission
(2097/4011 participants) were then additionally randomised to
stop their antihypertensive medications (intervention) or to con-
tinue pre-existing antihypertensive medications (control). Both
the GTN intervention and antihypertensive withdrawal were for
the first seven days following an acute stroke admission. There-
after medications could be prescribed or reintroduced as clinically
indicated.
Moonen 2015 was a parallel-group design RCT with two groups.
Over an initial six-week period, antihypertensivemedicationswere
withdrawn by the participant’s GP using a withdrawal algorithm
designed by the study authors. This was done provided systolic
blood pressure did not exceed 180mmHg.Medicationwithdrawal
was completed within four weeks from randomisation and con-
tinued for a period of three months thereafter.
Funding sources
The UKMedical Research Council funded Bath 2015 and a grant
from the Program Priority Medicines for the Elderly, the Nether-
landsOrganization forHealthResearch andDevelopment, funded
Moonen 2015.
Excluded studies
We excluded 77 publications, conference abstracts and registered
trials and presented the reasons for exclusion in the Characteristics
of excluded studies table. Reasons for study exclusion were: wrong
study design (not an RCT or CCT); wrong outcome measure
(lack of cognitive outcome measure used); wrong comparator (the
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study did not compare participants withdrawing antihypertensive
medications with participants continuing them); wrong interven-
tion (participants were not randomised to withdraw or continue
antihypertensive medications) and study protocol (planned work
without results reported; none met our eligibility criteria for in-
clusion as ongoing studies).
Risk of bias in included studies
Overall, the quality of included studies was high (see
Characteristics of included studies table, Figure 2), with the ex-
ception of high risk for performance and attrition bias in both
studies.
Allocation
Both studies were at low risk of selection bias as they used a central
computerised randomisation procedure for allocation of partici-
pants. Stratification was used to ensure that the groups were bal-
anced and key parameters appeared adequately divided between
intervention and control groups in each study.
Blinding
Both studies were at high risk of performance bias as neither
masked the participants or medical personnel associated with the
study to the treatment allocation. No placebo medications were
administered to participants who had usual antihypertensive ther-
apy withdrawn. Since the outcome measurement in each of the
two studies was blinded, this minimised the effect of bias on the
different outcome measures.
Both studies were at low risk of detection bias as outcome assess-
ment was conducted independently of the study team and asses-
sors were masked to the treatment allocation of the participants.
Incomplete outcome data
Overall, the risk of attrition bias was low for both studies because
they applied an intention-to-treat analysis. With respect to the pri-
mary outcome of this review, cognitive performance, both studies
were at high risk for attrition bias. We graded this as high risk for
attrition bias according to the GRADEproGDT 2015 guidelines
and reported this in Summary of findings for themain comparison.
Although both studies presented an intention-to-treat analysis for
their results, not all surviving participants received cognitive test-
ing at follow-up and the studies did not report the reasons to ac-
count for missing data. Bath 2015 reported cognitive assessment
on 1272 (telephone Mini-Mental State Examination (t-MMSE)
score) and 1179 (Telephone Interview forCognitive Status (TICS-
M) score), although 1784 survived at 90 days. Moonen 2015 re-
ported the intention-to-treat analysis for 356 participants, while
they randomised 388 participants. From those 356 participants,
data were missing for three in the intervention group and two
in the control group for their primary outcome (overall cognitive
function).
Selective reporting
Both studies were at low risk of reporting bias as outcomes were
reported as described in the published protocols. The protocol for
Moonen 2015 was included in the published paper as a supple-
mental appendix and the analysis plan for Bath 2015 was pub-
lished separately (Bath 2014).
Other potential sources of bias
Both studies were at low risk for other potential sources of bias as
none were identified.
Effects of interventions
See: Summary of findings for the main comparison
Antihypertensive withdrawal for the prevention of cognitive
decline
See Summary of findings for the main comparison for an overview
of the results.
Primary outcomes
Incident dementia
Neither study evaluated the presence of incident dementia at fol-
low-up.
Change in cognitive test scores
Cognitive function (at 90 days)
Bath 2015 report data at 90 days for cognitive assessment con-
ducted via the telephone. The numbers assessed in each group
were not reported and so the denominator used was the number
alive at 90 days. It is recognised this is an overestimate as the num-
ber alive at 90 days was 1784, whereas the number who received
a t-MMSE was 1272 and the TICS-M was 1179.
The t-MMSE score was a mean of 1.0 point higher in participants
who withdrew antihypertensive medications compared to partic-
ipants who continued them (95% CI 0.35 to 1.65; 1784 partici-
pants). The TICS-M was a mean of 2.10 points higher (95% CI
0.69 to 3.51; 1784 participants) (Figure 3; Figure 4). However,
in both cases, the evidence was of very low quality (downgraded
due to risk of bias from missing cognitive outcome data, evidence
from a single study and indirectness).
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Figure 3. Forest plot of comparison: 1 Cognitive function (at 90 days), outcome: 1.1 Telephone Mini-Mental
State Examination score.
Figure 4. Forest plot of comparison: 1 Cognitive function (at 90 days), outcome: 1.2 Modified Telephone
Interview for Cognitive Status score.
Change in cognitive performance (over 16 weeks)
Moonen 2015 report data for 351/388 participants on their pri-
mary outcome of cognitive performance using a composite of at
least five out of six cognitive tests. A higher score represented a bet-
ter cognitive performance. There was no evidence of a mean dif-
ference in cognitive performance between participants who with-
drew antihypertensive medications than participants who contin-
ued (MD 0.02 points, 95% CI -0.19 to 0.23; 351 participants)
(Figure 5). This evidence was of low quality (downgraded due to
risk of bias from missing cognitive outcome data and evidence
from a single study).
Figure 5. Forest plot of comparison: 2 Change in cognitive function (over 16 weeks), outcome: 2.1
Composite score.
Each of the six cognitive testswere reported independently for 356/
388 randomised participants. There was no evidence of change in
cognitive performance in participants who withdrew medications
using the MMSE score (MD 0.34 points, 95% CI -0.08 to 0.76;
356 participants); the 15-Word Verbal Learning Immediate Recall
score (MD 0.24 points, 95% CI -0.66 to 1.14; 356 participants);
the Delayed Recall score (MD 0.16 points, 95% CI -0.29 to 0.61;
356 participants); or the Visual Association Test score (MD 0.14
points, 95% CI -0.17 to 0.45; 356 participants). This evidence
was low quality (downgraded due to risk of bias from missing
cognitive outcome data and evidence from a single study).
There was no evidence of change in cognitive performance in par-
ticipants who withdrewmedications using the Stroop Interference
score (MD -2.22 points, 95% CI -9.62 to 5.18; 356 participants)
or the Trail Making Tests score (MD 10.06 points, 95% CI -2.20
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to 22.32; 356 participants). In both cases, evidence was very low
quality (downgraded due to risk of bias from missing cognitive
outcome data, imprecision and evidence from a single study).
Secondary outcomes
Change in systolic and diastolic blood pressure
Blood pressure at seven days
Systolic and diastolic blood pressure was assessed in 2095/2097
participants in Bath 2015, with missing data for the other two par-
ticipants. After seven days, systolic blood pressure was 9.5 mmHg
higher in the intervention compared to the control group (95%CI
7.43 to 11.57; 2095 participants) and diastolic blood pressure was
5.1 mmHg higher (95%CI 3.86 to 6.34; 2095 participants). This
evidence was low quality (downgraded due to indirectness from
the ability to interpret these data within the wider study looking
at GTN administration or not and evidence from a single study).
Change in systolic blood pressure (over 16 weeks)
Mean change in systolic and diastolic blood pressure was evaluated
for the 356 participants in Moonen 2015. Systolic blood pressure
increased by 7.4 mmHg in the withdrawal group compared to
the control group (95% CI 7.08 to 7.72; 356 participants) and
diastolic blood pressure increased by 2.6 mmHg (95% CI 2.42
to 2.78; 356 participants). This was moderate quality evidence
(downgraded due to evidence from a single study).
Adverse events
Mortality
Both studies reported data on mortality at follow-up (16 weeks
and 90 days) including all randomised participants for one study
(Bath 2015), and missing data on five randomised participants
in the other (Moonen 2015). There was no evidence that antihy-
pertensive medication withdrawal affected mortality at follow-up
(RR 0.88, 95% CI 0.72 to 1.08, I2 = 0%; 2485 participants; 2
studies; moderate quality evidence (downgraded due to indirect-
ness)) (Figure 6).
Figure 6. Forest plot of comparison: 4 Adverse events, outcome: 4.1 Mortality.
Cardiovascular events
Both studies reported on cardiovascular events during follow-up.
Moonen 2015 reported only myocardial infarction, while Bath
2015 reported myocardial infarction, sudden cardiac death and
other cardiovascular events. We pooled the results and there was
no evidence of effect of antihypertensive medication withdrawal
on the incidence of cardiovascular events (RR 1.29, 95% CI 0.96
to 1.72; I2 = 0%; 2485 participants; 2 studies; low quality evidence
(downgraded due to imprecision and indirectness)) (Figure 7).
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Figure 7. Forest plot of comparison: 4 Adverse events, outcome: 4.2 Cardiovascular events.
Falls
Neither study report data on incidence of falls.
Hospitalisations
Moonen 2015 reported incident hospitalisations. There was no
evidence that antihypertensive withdrawal reduced the risk of in-
cident hospitalisations (RR 0.85, 95% CI 0.36 to 2.06; 388 par-
ticipants; low quality evidence (downgraded due to imprecision
and evidence from a single study)).
Adherence to withdrawal
Bath 2015 reported adherence to allocated withdrawal or contin-
uation for the entire seven-day period of study. Data were available
for 2095/2097 included participants in the continue versus stop
arm. A total of 810/1044 participants in the intervention group
adhered to stopping antihypertensive therapy compare to 610/
1051 participants in the control group adhered to continuation
of antihypertensive therapy. Adherence to allocated treatment was
higher in participants withdrawing from antihypertensive medi-
cation than participants stopping (RR 1.34, 95% CI 1.26 to 1.42;
2095 participants; low quality evidence (downgraded due to indi-
rectness and as results from a single study)).
Moonen 2015 reported no data on adherence to withdrawal of
antihypertensive medications.
D I S C U S S I O N
Summary of main results
Despite a clear increase in blood pressure in the withdrawal groups
of both studies, there was no effect on cognition after seven days or
16weeks. There was also no effect on cardiovascular events ormor-
tality during the relatively short follow-up in the two studies. The
overall quality of the data from the two included studies was high
(Bath 2015;Moonen 2015).However, with respect to our primary
outcome measure, cognitive function, we downgraded evidence
when applying GRADE methodology (GRADEproGDT 2015).
For both studies, there was a risk of bias introduced from missing
cognitive outcomes data and analyses of cognition could not be
pooled, meaning data in each case were from a single study. There-
fore, we considered the evidence to be low quality for Moonen
2015 and very low quality for Bath 2015 as this was also consid-
ered indirect. To put these results in context, it is important to
state that our assessment of quality was in relation to our specific
study question and is not a statement on the quality of the in-
cluded trials themselves.
Dementia and cognitive performance
Neither study evaluated development of incident dementia fol-
lowing medication withdrawal. This lack of evidence for a key
question of interest to this review may reflect the short follow-
up periods used in both studies (90 days and 16 weeks). This
outcome measure is likely to require longer-term surveillance of
recruited participants, but would be of particular interest for the
DANTE study that included a population considered tohaveMCI
(Moonen 2015).
The data on cognitive performance is difficult to interpret with
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different results depending on the cognitive measure used. Fur-
thermore, determining the clinical significance of the changes ob-
served is key. Bath 2015 contains very low quality evidence of
improvement in cognitive performance at 90 days of follow-up;
however, we do not know the baseline cognitive function of the
included participants and cannot ascertain the effect of the acute
event (stroke) and the other intervention studied (nitric oxide)
from the effect of antihypertensive withdrawal for a seven-day pe-
riod. There is also a risk of a survival bias being introduced through
the study design, as only participants alive and able to complete
cognitive assessment at 90 days were included. Participants who
had died or could not be assessed in the telephone assessment were
excluded and this reflects the lower numbers in the cognitive anal-
yses. We had to use a proxy denominator in the form of ’alive at
90 days’ to incorporate the cognitive data. This overestimates the
numbers assessed and reduces confidence in the result presented.
Moonen 2015 used a composite cognitive score as their primary
outcome and we found low quality evidence that there was no
evidence of effect on cognitive performance in participants who
withdrew medications over the 16-week study period, compared
to participants who continued.
Blood pressure
We found lowquality evidence fromone study andmoderate qual-
ity evidence from the other study that systolic and diastolic blood
pressure rise following cessation of antihypertensive medications
when compared to participants who continue therapy. This clini-
cally plausible result is consistent; however, it does not appear to
be matched with any evidence of increased mortality (moderate
quality evidence) or cardiovascular events (low quality evidence).
The evidence for treating hypertension in older adults has been
established in randomised trials and is known to reduce cardiovas-
cular morbidity and mortality (Musini 2009).
Adverse events and safety
A rise in blood pressure may have been anticipated to lead to a
rise in adverse events. We found no evidence of a significant in-
crease in cardiovascular events (low quality evidence) or mortality
(moderate quality evidence) in either study. We recognise that the
studies had a relatively short period of follow-up (months) and
that it would take years of follow-up to be certain that the drug
withdrawal interventions had no effect on cardiovascular events.
Accepting this major caveat, as detailed in our protocol, we pooled
data from the available studies for common endpoints of mor-
tality and cardiovascular events. These pooled data suggested no
evidence of effect of antihypertensive medication withdrawal on
the incidence of cardiovascular events or mortality across the stud-
ies, albeit the ENOS study (Bath 2015) contributes almost all the
data.
Adherence to withdrawal
The results on adherence to withdrawal are difficult to interpret
as they could only be extracted from one study (Bath 2015), and
this also evaluated the effects of another medication (GTN) which
may lower blood pressure. It is difficult to conclude what effect this
had on the adherence of participants allocated to either arm of the
study. Data were not reported for participants who recommenced
medications in Moonen 2015 despite the inclusion of criteria for
re-introduction of medications.
Overall completeness and applicability of
evidence
Only one of the studies identified for inclusion in the review
aligned with our study question of interest, namely to examine
the cognitive effects of antihypertensive medication withdrawal
(Moonen 2015). Cognition was a secondary outcome measure
used by Bath 2015, whose primary question of interest was the sa-
fety and efficacy of nitric oxide in the context of acute stroke, with
or without continuing existing antihypertensive therapy. This af-
fects the extractable data available and limits the ability to compare
the two interventions.
Furthermore, although both populations were at high risk of cog-
nitive decline, the mechanism for these was clinically distinct.
Bath 2015 recruited people hospitalised for acute stroke who
were recruited into an intervention study of nitric oxide. Here
the expected rationale for withdrawing antihypertensive medica-
tion would be to maintain or augment blood pressure during an
acute (seven-day) period following stroke where itmay be plausible
to anticipate cerebral perfusion is acutely compromised (Markus
2004). Moonen 2015 recruited community-dwelling older adults
with evidence of reduced cognitive performance where withdraw-
ing medication could be considered to improve cerebral blood
flow where brain perfusionmay be chronically impaired (Mossello
2015). Both represent questions of clinical uncertainty and areas
of variation in practice.
The procedure for medication withdrawal in Moonen 2015 was
described in full in the supplementary material, overseen by the
participants’ GPs. The procedure used by Bath 2015 was not
clearly described. Many participants in the control group also ex-
perienced withdrawal of their medication as a consequence of im-
paired swallow following acute stroke, for part or all of the seven-
day period and only 67.8% of participants were adherent for all
seven days.
A particular limitation of the data presented is the inability to
combine cognitive scores and blood pressure data due to the vari-
ations in reporting between the papers. One argument is that the
populations were too distinct to pool data. However, if we are to
make best use of all available clinical trial data, greater effort must
be made in the reporting of outcomes using a more standardised
approach. Even if the data had been presented in the same format,
we could not have pooled scores as the measures used and the
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interventions itself were heterogeneous. This is an area of interest
beyond the scope of this review, reflected in international efforts
to standardise outcome measure reporting (ICHOM 2016). Ad-
ditionally, for some of the cognitive outcome measures used in the
included studies (t-MMSE in Bath 2015 and cognitive composite
score in Moonen 2015), the clinical significance of change in the
cognitive test scores is uncertain and this makes a result difficult
to interpret on a population level.
Also, neither study focused on the withdrawal of one particular an-
tihypertensive drug (class). Participants were allowed to stop their
previously described antihypertensive medications irrespective of
the class. We planned to do a subgroup analysis for the different
classes of antihypertensives, but due to a lack of data, this could
not be done.
Finally, the extent of excluded studies in relation to those eligible
for inclusion is important to explore. Two common reasons in-
cluded the design of the study, principally those identified were
observational in design and the lack of use of any cognitive out-
comemeasure at follow-up. The search strategy for this review was
comprehensive and designed to incorporate all studies looking at
the withdrawal of antihypertensive medications. However, current
indexing does not readily identify medication withdrawal studies
and this is an additional issue which would benefit from further
collaborative work to more easily identify deprescribing studies.
Quality of the evidence
Data from the two RCTs (2135 participants) could not be pooled
for analysis of change in cognitive test score. Evidence was of low
quality in relation to cognitive performance. Evidence was down-
graded in Moonen 2015 due to risk of bias from incomplete out-
come data and assessment of cognitive outcomes and evidence be-
ing from a single study. Evidence fromBath 2015 was downgraded
to very low quality for the same risk of bias and evidence from
a single study plus the indirectness associated with the compari-
son between blood pressure lowering with GTN and potential in-
teraction with the intervention studied (namely antihypertensive
medication withdrawal) as we could not establish who was in the
GTN and placebo study arms.
Data from the two RCTs (2135 participants) could not be pooled
for analysis of change in blood pressure due to the different re-
ported measures included and clinically distinct periods evalu-
ated. There was low quality evidence of mean systolic and diastolic
blood pressure being higher after seven days in participants who
stopped antihypertensive medications compared to participants
who continued them in Bath 2015, downgraded due to risk of
indirectness from the other intervention under study (GTN ad-
ministration) and evidence from a single study. There was mod-
erate quality evidence of mean rise in both systolic and diastolic
blood pressure after 10 weeks of follow-up after antihypertensive
medication withdrawal (total study period 16 weeks) in Moonen
2015, downgraded as evidence was from a single study.
On the basis of two RCTs (2485 participants) there was no ev-
idence of effect on mortality or cardiovascular events. However,
evidence for mortality was downgraded to moderate quality due
to the risk of indirectness associated with the majority of the par-
ticipants being people with acute stroke compared to community
dwellers with MCI. The evidence for cardiovascular events was
low quality in view of the same indirectness plus imprecision in
the result.
Adherence towithdrawal could only be assessed in one study (2095
participants) and the evidence here was considered low quality,
downgraded due to indirectness from the potential use of GTN
and the evidence being from a single small study.
No data were available on incidence of dementia or falls.
Potential biases in the review process
This reviewhas followedCochrane procedures and there were only
minor amendments to the review process from those stated in the
protocol, outlined in Differences between protocol and review.
Agreements and disagreements with other
studies or reviews
Cognitive impairment is considered as a significant factor in depre-
scribing decision-making by geriatricians (Ni Chroinin 2015) and
the lack of evidence for people with established dementia needs
to be addressed. Much of the developing evidence in this area is
not class-specific and is targeted at reducing the overall burden of
unnecessary medication use, particularly in the frail older-adult
population (Tjia 2013). One limitation of our approach may be
the focus on a single drug class, although this benefits from clarity
in observing the effect of withdrawal on drug-specific outcome
measures.
Antihypertensive medication withdrawal is a topic of interest not
only limited to cognitive effects. We await the results of a UK
feasibility study of antihypertensive medication withdrawal for
people with dementia (van der Wardt 2016).
There are other systematic reviews that have been looking to the
protecting effects of antihypertensive medications on cognition
(Levi Marpillat 2013; Tully 2016; Zhuang 2016), most of them
showing a protective effect of one or more drug classes. Despite
these results, it is also important to look at the effect on cognition
with drug withdrawal, since this reduces the polypharmacy and is
more cost-effective than continuing or introducing drugs.
This review is one of a suite of Cochrane Reviews, looking at with-
drawal of specific drug(s) or drug classes in the context of cogni-
tion. An additional Cochrane Review, describing antihypertensive
withdrawal with a non-cognitive focus is underway and will pro-
vide complementary data.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
It is uncertain whether withdrawal of antihypertensive medica-
tions has an influence on cognitionor canprevent dementia or cog-
nitive impairment in healthy adults or adults with impaired cog-
nition. Withdrawing antihypertensive drugs was associated with
increased blood pressure levels. It is unlikely to increase mortality
at three to four months’ follow-up, although there was a signal
from one large study looking at withdrawal after stroke that with-
drawal was associated an increase in cardiovascular events.
Implications for research
Review of the included and excluded studies suggests possible av-
enues for future drug withdrawal study design and conduct. For
our primary focus of antihypertensives and cognition, further re-
search should include older people and have suitably long follow-
up to capture changes in rates of cognitive decline or incident de-
mentia. A classical randomised controlled trial (RCT) design can
be used for deprescribing, just as it can for studies of new drugs,
although the need for a placebo or an alternative treatment in
the withdrawal group is debatable. For studies of withdrawal of
a drug class, such as antihypertensives, matched placebos would
be almost impossible to achieve for all different kinds of antihy-
pertensive treatment. Ideally, new RCTs looking at withdrawal of
antihypertensives (or other drugs) should standardise their cogni-
tive and other outcome measures. There are many ways to mea-
sure cognitive function, but these are not always comparable since
they may measure different cognitive domains. This heterogene-
ity precludes comparisons between studies and complicates meta-
analysis.
Deprescribing medications in general is becoming a major subject
for new research projects (deprescribing.org). Optimising med-
ication through deprescribing can be a vital part of managing
chronic conditions, reducing adverse effects and improving out-
comes, including cognitive outcomes. The deprescribing rubric
includes many approaches, withdrawal of all but essential drugs;
withdrawal of drugs considered to have increased risk in older
adults; withdrawal of drug classes and withdrawal of single agents.
Each approach is suited to a particular research question. For fu-
ture studies looking at antihypertensive withdrawal, a focus on
one type (class) of drug may be preferable, as cognitive effects may
vary with drug class and withdrawal studies which are too broad
maymiss important class-specific effects. The heterogeneity in ap-
proach to drug withdrawal that is included in the umbrella term
’deprescribing’ complicates systematic review. To progress the de-
prescribing agenda, we need agreed descriptive terms for the var-
ious approaches. As the literature on deprescribing research in-
creases, it may help future reviews if search filters for this study
methodology are developed.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bath 2015
Methods Design: randomised controlled parallel group trial
Date of study: 20 July 2001 to 14 October 2013
Sample size calculation: yes, needed 1750 for primary outcome
Inclusion criteria: adults with a clinical stroke syndrome with limb weakness lasting at
least 1 hour (i.e. not likely to be a transient ischaemic attack), residual limb weakness
at the time of enrolment, with onset < 48 hours, conscious (Glasgow Coma Scale >
8), systolic blood pressure in range 140 mmHg to 220 mmHg inclusive on the basis
of at least 1 of the 3 baseline prerandomisation measures, independent prior to stroke
(premorbid mRS < 2) and capable of a meaningful consent, or assent from a relative
or carer if the person was unable to give meaningful consent (e.g. in cases of dysphasia,
confusion or reduced conscious level)
Exclusion criteria: a definite need to start (e.g. for thrombolysis), continue or stop blood
pressure lowering drugs; need for, or contraindication to, glyceryl trinitrate; coma (Glas-
gow coma scale score < 8); pure sensory stroke; isolated dysphasia; preceding moderate or
severe dependency (mRS score 3 to 5); confounding neurological or psychiatric disease;
a disorder mimicking stroke (e.g. hypoglycaemia, Todd’s paresis); liver dysfunction (in-
ternational normalised ratio > 1.5, aminotransferase > 3 times normal concentrations)
or renal dysfunction (creatinine > 3 times normal concentrations); severe concomitant
medical disorder; pregnancy or breastfeeding; previous participation in the ENOS trial;
planned surgical intervention or participation in another trial within 2 weeks
Participants Number in study: 2097
Country: international multicentre
Setting: acute hospitalisation for stroke
Age mean (SD): 73 (11) years
Sex: intervention 52% men; control 50% men
Comorbidity: assessed and comparable at baseline
Level of education: not reported
Dementia: cognitive status not assessed at baseline
Interventions Intervention: withdrawal of pre-existing antihypertensive medications for 7 days follow-
ing stroke
Control: continue pre-existing antihypertensive medications following stroke
Outcomes Measured at 90 days:
• t-MMSE
• TICS-M
• blood pressure
• mortality
• adherence to withdrawal
• serious adverse events (including myocardial infarction)
Notes Funding source: UK Medical Research Council
Declaration of interest: “We declare no competing interests”
28Antihypertensive withdrawal for the prevention of cognitive decline (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bath 2015 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: they used stratification and
minimisation to ensure that the groups
were balanced for prognostic factors, and
the random element reduced predictability
Allocation concealment (selection bias) Low risk Quote: “Central computer based system.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: not blinded for participant or
personnel if the antihypertensive medica-
tion was stopped
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The coordinating centre of each
country (masked to treatment allocation)
did the final follow-up centrally at 90 days
by telephone.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: they applied an intention-to-
treat analysis. For primary outcome of this
review: 1778 participants alive at 90 days’
follow-up and so eligible for cognitive as-
sessment. Results table reported t-MMSE
data for 1272 participants and TICS-M
data for 1179 participants - no explanation
provided for missing assessment data
Selective reporting (reporting bias) Low risk Comment: outcomes reported as described
in published protocol
Other bias Low risk Comment: none were identified.
Moonen 2015
Methods Design: randomised controlled parallel group trial
Date of study: 26 June 2011 to 23 August 2013
Sample size calculation: yes, 400 participants required for primary outcome
Inclusion criteria: aged≥ 75 years, used antihypertensive treatment, systolic blood pres-
sure ≤ 160 mm Hg and had an MMSE score of 21 to 27
Exclusion criteria: a clinical diagnosis of dementia, use of antihypertensives for reasons
other than hypertension, current angina pectoris, cardiac arrhythmia, heart failure, my-
ocardial infarction or a coronary reperfusion procedure < 3 years ago, a history of stroke
or transient ischaemic attack or a limited life expectancy
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Moonen 2015 (Continued)
Participants Number in study: 393
Country: the Netherlands
Setting: community primary care
Age mean (SD): intervention 81.1 (4.3) years; control 81.5 (4.6) years
Sex: intervention 77% men; control 70% men
Comorbidity: assessed and comparable at baseline
Level of education: assessed and comparable at baseline
Dementia: people with existing dementia were excluded
Interventions Intervention: discontinuation of antihypertensive medications over a 6-week period after
randomisation using a withdrawal algorithm with outcome assessment at 16 weeks
Control: blood pressure medication continued. Blood pressure recorded at 6 and 10
weeks postrandomisation and at 16 weeks
Outcomes Measured after 16 weeks:
• Overall cognition (compound score): computed if 5 of the following 6 tests were
available: Stroop-Colour Word Test and Trail Making Test for executive functioning,
15-Word Verbal Learning Test and Visual Association Test for (immediate and delayed)
verbal and picture memory and Letter-Digit Substitution Test for psychomotor speed
• MMSE for global cognitive functioning
• Blood pressure
• Mortality
• Adherence to withdrawal
• Serious adverse events (including myocardial infarction, hospitalisations)
Notes Funding source: this study was supported by a grant from Program Priority Medicines
for the Elderly, the Netherlands Organization for Health Research and Development
(Project 113101003)
Declaration of interest: “None reported”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Participants were randomly as-
signed, in a 1:1 ratio, to parallel discontinu-
ation (intervention group) or continuation
(control group) of anti- hypertensive treat-
ment
The allocation was generated by a central
computerized randomisation procedure in
a 1:1 ratio in stratified block randomisa-
tion.”
Allocation concealment (selection bias) Low risk Quote: “Stratified block randomisation
was used (with block sizes of 4 per gen-
eral practice) to ensure that intervention
and control participants were equally dis-
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Moonen 2015 (Continued)
tributed within general practices
Concealment of treatment allocation was
ensured by a central computerized ran-
domisation procedure.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “Participants and the physicians
conducting the intervention were not
masked to the allocated intervention.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “At baseline and at the follow-up 16
weeks after randomisation, blood pressure
wasmeasured and cognitive, psychological,
and general daily functioning were assessed
by trained blinded research personnel dur-
ing home visits
Study outcomes ... were assessed in a stan-
dardized manner by research personnel
masked to the allocated intervention.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: intention-to-treat analysis in
both groups. However, cognitive assess-
ment data missing for primary outcome
without explanation provided
Selective reporting (reporting bias) Low risk Comment: outcomes reported as described
in published protocol
Other bias Low risk Comment: no evidence of other bias.
ENOS: Efficacy of Nitric Oxide in Stroke; MMSE: Mini-Mental State Examination; mRS: modified Rankin Scale; SD: standard
deviation; t-MMSE: Telephone-Mini Mental State Examination; TICS-M: Modified Telephone Interview for Cognitive Status.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aberg 1989 Not an RCT
ADVANCE 2001 Study protocol, study not included
Al-Qassab 1988 No cognitive outcomes
Alabaster 1983 Not an RCT
Alderman 1985 Not an RCT
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(Continued)
Alderman 1986 Not an RCT
Andersen 2003 No cognitive outcomes
Andersen 2009 No cognitive outcomes
Anonymous 1975 Not an RCT
Appel 1995 Study protocol, study not included
Ashford 1986 Not an RCT
Aylett 1994 Not an RCT
Aylett 1999 Not an RCT
Benetos 2015b Not an RCT
Bevan 1993 No cognitive outcomes
Blaufox 1984 No cognitive outcomes
Blom 1993 No cognitive outcomes
Bouzas-Mosquera 2008 Not an RCT
Boyle 1979 Not an RCT
Braunschweig 2002 Not an RCT
Brundin 1976 Not an RCT
Burton 1991 Not an RCT
Böhm 2015 Wrong comparator, no withdrawal of an antihypertensive
Charalabopoulos 2005 Not an RCT
Choulerton 2010 Not an RCT
Chrysant 1978 Not an RCT
Cooper 1988 Not an RCT
Croft 1986 No cognitive outcomes
Cullhed 1976 Not an RCT
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(Continued)
Danielson 1981 Not an RCT
Danilevicius 1977 Not an RCT
Deckert 1994 Not an RCT
Düsing 2012 No cognitive outcomes
Ekbom 1994 Not an RCT
ENOS Trial Investigators 2006 Study protocol, study included
Espeland 1999 No cognitive outcomes
Fagerberg 1992 Not an RCT
Fernandez 1982 Not an RCT
Finnerty 1985 Not an RCT
Froom 1997 Not an RCT
Giles 1988 No cognitive outcomes
Goldberg 1977 Not an RCT
Grimm 1997 Not an RCT
Guthrie 2002 No cognitive outcomes
Hajjar 2013 Not an RCT
Hansen 1983 Not an RCT
Hansen 1985 Not an RCT
Hearing 1999 All participants were originally taking atenolol and the intervention group withdrew
the atenolol, but received an angiotensin converting enzyme inhibitor instead. Since
the antihypertensive treatment was replaced with another antihypertensive treatment,
we found this intervention not suitable for this review
Ho 1994 No cognitive outcomes
ISRCTN31208535 Wrong intervention, there is no antihypertensive treatment withdrawn. Still in re-
cruitment phase
ISRCTN82856726 Wrong intervention, there is no antihypertensive treatment withdrawn. Still in re-
cruitment phase
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(Continued)
ISRCTN93682878 Wrong intervention, there is no antihypertensive treatment withdrawn. Still in re-
cruitment phase
Iyer 2008 Not an RCT
Kostis 1998 No cognitive outcomes
Kuramoto 1978 Not an RCT
Langford 1984 No cognitive outcomes
Langford 1985 No cognitive outcomes
Maland 1983 No cognitive outcomes
Maling 1979 Not an RCT
Mehta 1994 No cognitive outcomes
Middeke 1990 No cognitive outcomes
Nedogoda 2012 Wrong comparator, there is no withdrawal of antihypertensive treatment
Olsson 1986 No cognitive outcomes
Peart 1986 No cognitive outcomes
Pflugfelder 1993 No cognitive outcomes
PROGRESS Management Committee 1996 Study protocol, study not included
Ruoff 1986 No cognitive outcomes
Sever 1991 Not an RCT
Szecsi 1982 No cognitive outcomes
Takata 1992 No cognitive outcomes
Thaler 1993 No cognitive outcomes
Thomas 2006 Study protocol, study not included
van Wel 2011 No withdrawal of antihypertensive treatment
Vaur 1998 No cognitive outcomes
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Walma 1997 No cognitive outcomes
Wan 2010 Not an RCT
RCT: randomised controlled trial.
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D A T A A N D A N A L Y S E S
Comparison 1. Cognitive function (at 90 days)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Telephone Mini-Mental State
Examination score
1 Mean Difference (IV, Random, 95% CI) Subtotals only
2 Modified Telephone Interview
for Cognitive Status score
1 Mean Difference (IV, Random, 95% CI) Subtotals only
Comparison 2. Change in cognitive function (over 16 weeks)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Composite score 1 Mean Difference (IV, Random, 95% CI) Subtotals only
2 Mini-Mental State Examination
score
1 Mean Difference (IV, Random, 95% CI) Subtotals only
3 Stroop Interference score 1 Mean Difference (IV, Random, 95% CI) Subtotals only
4 Trail making test score 1 Mean Difference (IV, Random, 95% CI) Subtotals only
5 15-Word Verbal Learning
Immediate Recall score
1 Mean Difference (IV, Random, 95% CI) Subtotals only
6 15-Word Verbal Learning
Delayed Recall score
1 Mean Difference (IV, Random, 95% CI) Subtotals only
7 Visual Association Test score 1 Mean Difference (IV, Random, 95% CI) Subtotals only
Comparison 3. Blood pressure (at 7 days)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Systolic blood pressure 1 Mean Difference (IV, Random, 95% CI) Subtotals only
2 Diastolic blood pressure 1 Mean Difference (IV, Random, 95% CI) Subtotals only
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Comparison 4. Change in blood pressure (at 16 weeks)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Systolic blood pressure 1 Mean Difference (IV, Random, 95% CI) Subtotals only
2 Diastolic blood pressure 1 Mean Difference (IV, Random, 95% CI) Subtotals only
Comparison 5. Adverse events
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 2 2485 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.72, 1.08]
1.1 Mortality within 90 days 1 2097 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.72, 1.08]
1.2 Mortality within 16 weeks 1 388 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.06, 15.08]
2 Cardiovascular events 2 2485 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.96, 1.72]
2.1 Any cardiovascular events
within 90 days
1 2097 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.97, 1.72]
2.2 Myocardial infarction
within 16 weeks
1 388 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.06, 15.08]
3 Hospitalisation within 16 weeks 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
Comparison 6. Adherence to withdrawal
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Adherence over all 7 days 1 2095 Risk Ratio (M-H, Random, 95% CI) 1.34 [1.26, 1.42]
Analysis 1.1. Comparison 1 Cognitive function (at 90 days), Outcome 1 Telephone Mini-Mental State
Examination score.
Review: Antihypertensive withdrawal for the prevention of cognitive decline
Comparison: 1 Cognitive function (at 90 days)
Outcome: 1 Telephone Mini-Mental State Examination score
Study or subgroup AH withdrawal AH continuation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bath 2015 898 10 (7) 886 9 (7) 1.00 [ 0.35, 1.65 ]
-2 -1 0 1 2
Favours withdrawal Favours continuation
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Analysis 1.2. Comparison 1 Cognitive function (at 90 days), Outcome 2 Modified Telephone Interview for
Cognitive Status score.
Review: Antihypertensive withdrawal for the prevention of cognitive decline
Comparison: 1 Cognitive function (at 90 days)
Outcome: 2 Modified Telephone Interview for Cognitive Status score
Study or subgroup AH withdrawal AH continuation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bath 2015 898 21.11 (15.08) 886 19.01 (15.23) 2.10 [ 0.69, 3.51 ]
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours withdrawal Favours continuation
Analysis 2.1. Comparison 2 Change in cognitive function (over 16 weeks), Outcome 1 Composite score.
Review: Antihypertensive withdrawal for the prevention of cognitive decline
Comparison: 2 Change in cognitive function (over 16 weeks)
Outcome: 1 Composite score
Study or subgroup AH withdrawal AH continuation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Moonen 2015 177 0.01 (1.0112) 174 -0.01 (1.0025) 0.02 [ -0.19, 0.23 ]
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours withdrawal Favours continuation
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Analysis 2.2. Comparison 2 Change in cognitive function (over 16 weeks), Outcome 2 Mini-Mental State
Examination score.
Review: Antihypertensive withdrawal for the prevention of cognitive decline
Comparison: 2 Change in cognitive function (over 16 weeks)
Outcome: 2 Mini-Mental State Examination score
Study or subgroup AH withdrawal AH continuation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Moonen 2015 180 1.15 (2.0397) 176 0.81 (2.0166) 0.34 [ -0.08, 0.76 ]
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Change in cognitive function (over 16 weeks), Outcome 3 Stroop Interference
score.
Review: Antihypertensive withdrawal for the prevention of cognitive decline
Comparison: 2 Change in cognitive function (over 16 weeks)
Outcome: 3 Stroop Interference score
Study or subgroup AH withdrawal AH continuation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Moonen 2015 180 -4.05 (35.8985) 176 -1.83 (35.3574) -2.22 [ -9.62, 5.18 ]
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Change in cognitive function (over 16 weeks), Outcome 4 Trail making test
score.
Review: Antihypertensive withdrawal for the prevention of cognitive decline
Comparison: 2 Change in cognitive function (over 16 weeks)
Outcome: 4 Trail making test score
Study or subgroup AH withdrawal AH continuation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Moonen 2015 180 9.07 (58.7429) 176 -0.99 (59.2875) 10.06 [ -2.20, 22.32 ]
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Change in cognitive function (over 16 weeks), Outcome 5 15-Word Verbal
Learning Immediate Recall score.
Review: Antihypertensive withdrawal for the prevention of cognitive decline
Comparison: 2 Change in cognitive function (over 16 weeks)
Outcome: 5 15-Word Verbal Learning Immediate Recall score
Study or subgroup AH withdrawal AH continuation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Moonen 2015 180 1.17 (4.2833) 176 0.93 (4.3693) 0.24 [ -0.66, 1.14 ]
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 Change in cognitive function (over 16 weeks), Outcome 6 15-Word Verbal
Learning Delayed Recall score.
Review: Antihypertensive withdrawal for the prevention of cognitive decline
Comparison: 2 Change in cognitive function (over 16 weeks)
Outcome: 6 15-Word Verbal Learning Delayed Recall score
Study or subgroup AH withdrawal AH continuation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Moonen 2015 180 0.47 (2.1757) 176 0.31 (2.151) 0.16 [ -0.29, 0.61 ]
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Change in cognitive function (over 16 weeks), Outcome 7 Visual Association
Test score.
Review: Antihypertensive withdrawal for the prevention of cognitive decline
Comparison: 2 Change in cognitive function (over 16 weeks)
Outcome: 7 Visual Association Test score
Study or subgroup AH withdrawal AH continuation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Moonen 2015 180 0.1 (1.4958) 176 -0.04 (1.4788) 0.14 [ -0.17, 0.45 ]
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Blood pressure (at 7 days), Outcome 1 Systolic blood pressure.
Review: Antihypertensive withdrawal for the prevention of cognitive decline
Comparison: 3 Blood pressure (at 7 days)
Outcome: 1 Systolic blood pressure
Study or subgroup AH withdrawal AH continuation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bath 2015 1044 155.1 (23.9) 1051 145.6 (24.5) 9.50 [ 7.43, 11.57 ]
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Blood pressure (at 7 days), Outcome 2 Diastolic blood pressure.
Review: Antihypertensive withdrawal for the prevention of cognitive decline
Comparison: 3 Blood pressure (at 7 days)
Outcome: 2 Diastolic blood pressure
Study or subgroup AH withdrawal AH continuation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bath 2015 1044 85.1 (14.3) 1051 80 (14.7) 5.10 [ 3.86, 6.34 ]
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Change in blood pressure (at 16 weeks), Outcome 1 Systolic blood pressure.
Review: Antihypertensive withdrawal for the prevention of cognitive decline
Comparison: 4 Change in blood pressure (at 16 weeks)
Outcome: 1 Systolic blood pressure
Study or subgroup AH withdrawal AH continuation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Moonen 2015 180 5.4 (1.6) 176 -2 (1.5) 7.40 [ 7.08, 7.72 ]
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 Change in blood pressure (at 16 weeks), Outcome 2 Diastolic blood pressure.
Review: Antihypertensive withdrawal for the prevention of cognitive decline
Comparison: 4 Change in blood pressure (at 16 weeks)
Outcome: 2 Diastolic blood pressure
Study or subgroup AH withdrawal AH continuation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Moonen 2015 180 1.3 (0.9) 176 -1.3 (0.8) 2.60 [ 2.42, 2.78 ]
Test for subgroup differences: Not applicable
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Analysis 5.1. Comparison 5 Adverse events, Outcome 1 Mortality.
Review: Antihypertensive withdrawal for the prevention of cognitive decline
Comparison: 5 Adverse events
Outcome: 1 Mortality
Study or subgroup AH withdrawal AH continuation Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mortality within 90 days
Bath 2015 146/1044 167/1053 99.5 % 0.88 [ 0.72, 1.08 ]
Subtotal (95% CI) 1044 1053 99.5 % 0.88 [ 0.72, 1.08 ]
Total events: 146 (AH withdrawal), 167 (AH continuation)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
2 Mortality within 16 weeks
Moonen 2015 1/199 1/189 0.5 % 0.95 [ 0.06, 15.08 ]
Subtotal (95% CI) 199 189 0.5 % 0.95 [ 0.06, 15.08 ]
Total events: 1 (AH withdrawal), 1 (AH continuation)
Heterogeneity: not applicable
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(Continued . . . )
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(. . . Continued)
Study or subgroup AH withdrawal AH continuation Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 1243 1242 100.0 % 0.88 [ 0.72, 1.08 ]
Total events: 147 (AH withdrawal), 168 (AH continuation)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
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Analysis 5.2. Comparison 5 Adverse events, Outcome 2 Cardiovascular events.
Review: Antihypertensive withdrawal for the prevention of cognitive decline
Comparison: 5 Adverse events
Outcome: 2 Cardiovascular events
Study or subgroup AH withdrawal AH continuation Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Any cardiovascular events within 90 days
Bath 2015 96/1044 75/1053 98.9 % 1.29 [ 0.97, 1.72 ]
Subtotal (95% CI) 1044 1053 98.9 % 1.29 [ 0.97, 1.72 ]
Total events: 96 (AH withdrawal), 75 (AH continuation)
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.084)
2 Myocardial infarction within 16 weeks
Moonen 2015 1/199 1/189 1.1 % 0.95 [ 0.06, 15.08 ]
Subtotal (95% CI) 199 189 1.1 % 0.95 [ 0.06, 15.08 ]
Total events: 1 (AH withdrawal), 1 (AH continuation)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Total (95% CI) 1243 1242 100.0 % 1.29 [ 0.96, 1.72 ]
Total events: 97 (AH withdrawal), 76 (AH continuation)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.086)
Test for subgroup differences: Chi2 = 0.05, df = 1 (P = 0.83), I2 =0.0%
0.05 0.2 1 5 20
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Analysis 5.3. Comparison 5 Adverse events, Outcome 3 Hospitalisation within 16 weeks.
Review: Antihypertensive withdrawal for the prevention of cognitive decline
Comparison: 5 Adverse events
Outcome: 3 Hospitalisation within 16 weeks
Study or subgroup AH withdrawal AH continuation Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Moonen 2015 9/199 10/189 0.85 [ 0.36, 2.06 ]
Test for subgroup differences: Not applicable
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Analysis 6.1. Comparison 6 Adherence to withdrawal, Outcome 1 Adherence over all 7 days.
Review: Antihypertensive withdrawal for the prevention of cognitive decline
Comparison: 6 Adherence to withdrawal
Outcome: 1 Adherence over all 7 days
Study or subgroup AH withdrawal AH continuation Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bath 2015 810/1044 610/1051 100.0 % 1.34 [ 1.26, 1.42 ]
Total (95% CI) 1044 1051 100.0 % 1.34 [ 1.26, 1.42 ]
Total events: 810 (AH withdrawal), 610 (AH continuation)
Heterogeneity: not applicable
Test for overall effect: Z = 9.35 (P < 0.00001)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Baseline characteristics of participants and main interventions of included studies
Study Number of
randomised partici-
pants
Type of antihyper-
tensive
Mean age in years
(SD)
Male sex (%) Cognitive Outcomes
Bath 2015 Total 2097
IG 1044
CG 1053
No restric-
tions: any previously
prescribed antihyper-
tensive treatment to
be withdrawn
73 (11) 51% Assessed at 90-day follow-
up:
• t-MMSE
• TICS-M
Moonen 2015 Total 393
IG 199 (180 in ITT
analysis)
CG 186 (176 in ITT
analysis)
No restric-
tions: any previously
prescribed antihyper-
tensive treatment to
be withdrawn
IG: 81.1 (4.3)
CG: 81.5 (4.6)
41% Assessed at baseline and 16-
week follow-up; reported as
change in performance:
• Overall cognition
(compound score): Stroop
Interference, TMT, 15-
WVLT Immediate Recall,
15-WVLT Delayed Recall,
VAT and LDST
• MMSE
• SCWT
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Table 1. Baseline characteristics of participants and main interventions of included studies (Continued)
• TMT
• 15-WVLT
• VAT
• LDST
15-WVLT: 15-Word Verbal Learning Test; CG: control group; IG: intervention group; ITT: intention to treat; LDST: Letter-Digit
Substitution Test; MMSE:Mini-Mental State Examination; SCWT: Stroop-ColourWord Test; TICS-M:Modified Telephone Inter-
view for Cognitive Status; t-MMSE: telephone Mini-Mental State Examination; TMT: Trail Making Test; VAT: Visual Association
Test.
A P P E N D I C E S
Appendix 1. All medications with antihypertensive function (irrespective of indication)
Loop diuretics: bumetanide, ethacrynic acid, furosemide, torsemide
Thiazide diuretics: epitizide, hydrochlorothiazide and chlorothiazide, bendroflumethiazide, xipamide
Thiazide-like diuretics: indapamide, chlorthalidone, metolazone
Potassium-sparing diuretics: amiloride, triamterene
Dihydropyridines: amlodipine, cilnidipine, felodipine, isradipine, lercanidipine, levamlodipine, nicardipine, nifedipine, nimodipine,
nitrendipine, barnidipine, lacidipine, aranidipine, azelnidipine, benidipine, clevidipine, darodipine, efonidipine, manidipine, niguldip-
ine, nilvadipine, nisoldipine, nitrendipine, oxodipine, pranidipine
Non-dihydropyridines: diltiazem, verapamil
ACE-inhibitors: captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril, benazepril, zofenopril, imi-
dapril, cilazapril
Angiotensin II receptor antagonists: candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, azilsartan, fimasar-
tan
Beta blockers: atenolol, metoprolol, nadolol, nebivolol, oxprenolol, pindolol, propranolol, timolol, bisoprolol, acebutolol, celiprolol,
esmolol, sotalol
Alpha blockers: doxazosin, phentolamine, indoramin, phenoxybenzamine, prazosin, terazosin, tolazolin, ketanserin, urapidil, fentolamin
Mixed Alpha + Beta blockers: carvedilol, labetalol
Vasodilators: hydralazine, minoxidil
Renin Inhibitors: aliskiren
Aldosterone receptor antagonists: eplerenone, spironolactone
Alpha-2 adrenergic receptor agonists: clonidine, guanabenz, guanfacine, methyldopa, moxonidine, guanethidine, mecamylamine
Other: magnesium sulfate
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Appendix 2. Search strategies
Source Search strategy Hits retrieved
1. ALOIS (www.medicine.ox.ac.uk/alois)
[searched 12 December 2015]
(antihypertensive* or “anti-hypertensive*”)
AND withdraw*
4
2. MEDLINE In-process and other non-
indexed citations and MEDLINE 1946-
present (OvidSP)
[searched 12 December 2015]
1. (antihypertensive* or “anti-hyperten-
sive*” or “angiotensin converting enzyme
inhibitor*” or (angiotensin adj2 receptor
antagonist*) or (angiotensin adj2 receptor
block*) or “AT 2 receptor block*” or “AT 2
receptor antagon*” or ARB or ARBs or acei
or ace-I or (ace adj2 inhibitor*) or “adren-
ergic beta antagonist*” or “adrenergic al-
pha antagonist*” or “beta block*” or “al-
pha block*” or diuretic* or “calcium chan-
nel blocker*” orCCBorCCBs or chloroth-
iazide or chlorthalidone or hydralazine or
hydrochlorothiazide or minoxidil or cap-
topril or enalapril or fosinopril or lisino-
pril or ramipril or losartan or irbesartan
or candesartan or eprosartan or valsartan
or olmesartan or telmisartan or amlodip-
ine or diltiazemor felodipine or nicardipine
or nifedipine or nimodipine or verapamil
or alprenolol or atenolol or metoprolol or
nadolol or oxprenolol or pindolol or pro-
pranolol or labetalol or prazosin or spirono-
lactone or triamterene or bumetanide or
furosemide or indapamide or frusemide or
diazoxide or eplerenone or amiloride or
clonidine or methyldopa or isradipine or
xipamide or barnidipine or lacidipine or
aranidipine or azelnidipine or benidipine
or clevidipine or darodipine or efonidipine
or manidipine or niguldipine or nilvadip-
ine or nisoldipine or nitrendipine or ox-
odipine or pranidipine or zofenopril or im-
idapril or cilazapril or azilsartan or fimasar-
tan or bisoprolol or acebutolol or celiprolol
or esmolol or sotalol or ketanserin or ura-
pidil or fentolamin or minoxidil or “mag-
nesium sulphate”).ti,ab
2. exp Antihypertensive Agents/
3. Hypertension/dt [Drug Therapy]
4. exp Angiotensin-Converting Enzyme
Inhibitors/
5. exp Angiotensin Receptor Antagonists/
6371
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(Continued)
6. Angiotensin II/ai [Antagonists & In-
hibitors]
7. exp Adrenergic beta-Antagonists/
8. exp Adrenergic alpha-Antagonists/
9. exp Diuretics/
10. exp Calcium Channel Blockers/
11. Chlorothiazide/
12. Chlorthalidone/
13. Hydralazine/
14. Hydrochlorothiazide/
15. Minoxidil/
16. Captopril/
17. Enalapril/
18. Fosinopril/
19. Lisinopril/
20. Ramipril/
21. Losartan/
22. or/1-21
23. withdraw*.mp.
24. cessat*.mp.
25. (reduce* or reducing* or reduct*).mp.
26. taper*.mp.
27. stop*.mp.
28. (“carr* on” or continuation).mp.
29. (“come off” or “taken off”).mp.
30. or/23-29
31. 22 and 30
32. randomized controlled trial.pt.
33. controlled clinical trial.pt.
34. random*.ab.
35. placebo.ab.
36. drug therapy.fs.
37. trial.ab.
38. groups.ab.
39. “double-blind*”.ti,ab.
40. “single-blind*”.ti,ab.
41. or/32-40
42. 31 and 41
43. (cognition or cognitive).ti,ab.
44. (memory or “executive function*” or
brain or mental).ti,ab
45. Cognition/
46. Cognition Disorders/
47. Memory/
48. Delirium, Dementia, Amnestic, Cog-
nitive Disorders/ or Dementia/
49. or/43-48
50. 42 and 49
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(Continued)
51. exp *Antihypertensive Agents/
52. exp *Hypertension/
53. (antihypertensive* or “anti-hyperten-
sive*” or “angiotensin converting enzyme
inhibitor*” or (angiotensin adj2 receptor
antagonist*) or (angiotensin adj2 receptor
block*) or “AT 2 receptor block*” or “AT 2
receptor antagon*” or ARB or ARBs or acei
or ace-I or (ace adj2 inhibitor*) or “adren-
ergic beta antagonist*” or “adrenergic al-
pha antagonist*” or “beta block*” or “al-
pha block*” or diuretic* or “calcium chan-
nel blocker*”).ti,ab
54. or/51-53
55. withdraw*.ti,ab.
56. 41 and 54 and 55
57. 50 or 56
3. EMBASE
1974-2015 December 09 (OvidSP)
[searched 12 December 2015]
1. (antihypertensive* or “anti-hyperten-
sive*” or “angiotensin converting enzyme
inhibitor*” or (angiotensin adj2 receptor
antagonist*) or (angiotensin adj2 receptor
block*) or “AT 2 receptor block*” or “AT 2
receptor antagon*” or ARB or ARBs or acei
or ace-I or (ace adj2 inhibitor*) or “adren-
ergic beta antagonist*” or “adrenergic al-
pha antagonist*” or “beta block*” or “al-
pha block*” or diuretic* or “calcium chan-
nel blocker*” orCCBorCCBs or chloroth-
iazide or chlorthalidone or hydralazine or
hydrochlorothiazide or minoxidil or cap-
topril or enalapril or fosinopril or lisino-
pril or ramipril or losartan or irbesartan
or candesartan or eprosartan or valsartan
or olmesartan or telmisartan or amlodip-
ine or diltiazemor felodipine or nicardipine
or nifedipine or nimodipine or verapamil
or alprenolol or atenolol or metoprolol or
nadolol or oxprenolol or pindolol or pro-
pranolol or labetalol or prazosin or spirono-
lactone or triamterene or bumetanide or
furosemide or indapamide or frusemide or
diazoxide or eplerenone or amiloride or
clonidine or methyldopa or isradipine or
xipamide or barnidipine or lacidipine or
aranidipine or azelnidipine or benidipine
or clevidipine or darodipine or efonidipine
or manidipine or niguldipine or nilvadip-
ine or nisoldipine or nitrendipine or ox-
3245
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(Continued)
odipine or pranidipine or zofenopril or im-
idapril or cilazapril or azilsartan or fimasar-
tan or bisoprolol or acebutolol or celiprolol
or esmolol or sotalol or ketanserin or ura-
pidil or fentolamin or minoxidil or “mag-
nesium sulphate”).ti,ab
2. antihypertensive agent/
3. hypertension/
4. dipeptidyl carboxypeptidase inhibitor/
5. angiotensin receptor antagonist/
6. angiotensin II/
7. beta adrenergic receptor blocking agent/
8. alpha adrenergic receptor blocking
agent/
9. diuretic agent/
10. calcium channel blocking agent/
11. chlorothiazide/
12. chlortalidone/
13. hydralazine/
14. hydrochlorothiazide/
15. minoxidil/
16. captopril/
17. enalapril/
18. fosinopril/
19. lisinopril/
20. ramipril/
21. losartan/
22. irbesartan/
23. or/1-22
24. treatment withdrawal/ or drug with-
drawal/
25. withdraw*.ti,ab.
26. cessat*.ti,ab.
27. (reduce* or reducing* or reduct*).ti,ab.
28. taper*.ti,ab.
29. stop*.ti,ab.
30. (“carr* on” or continuation).ti,ab.
31. (“come off” or “taken off”).ti,ab.
32. or/24-31
33. 23 and 32
34. (cognition or cognitive).ti,ab.
35. (memory or “executive function*” or
brain or mental).ti,ab
36. cognition/
37. dementia/
38. dement*.ti,ab.
39. or/34-38
40. 33 and 39
52Antihypertensive withdrawal for the prevention of cognitive decline (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
41. randomized controlled trial/
42. controlled clinical trial/
43. random$.ti,ab.
44. randomization/
45. intermethod comparison/
46. placebo.ti,ab.
47. (compare or compared or comparison)
.ti.
48. ((evaluated or evaluate or evaluating or
assessed or assess) and (compare or com-
pared or comparing or comparison)).ab
49. (open adj label).ti,ab.
50. ((double or single or doubly or singly)
adj (blind or blinded or blindly)).ti,ab
51. double blind procedure/
52. parallel group$1.ti,ab.
53. (crossover or cross over).ti,ab.
54. ((assign$ or match or matched or al-
location) adj5 (alternate or group$1 or in-
tervention$1 or patient$1 or subject$1 or
participant$1)).ti,ab
55. (assigned or allocated).ti,ab.
56. (controlled adj7 (study or design or
trial)).ti,ab.
57. (volunteer or volunteers).ti,ab.
58. trial.ti.
59. or/41-58
60. 40 and 59
4. PSYCINFO
1806-December week 2 2015 (OvidSP)
[searched 12 December 2015]
1. (antihypertensive* or “anti-hyperten-
sive*” or “angiotensin converting enzyme
inhibitor*” or (angiotensin adj2 receptor
antagonist*) or (angiotensin adj2 receptor
block*) or “AT 2 receptor block*” or “AT 2
receptor antagon*” or ARB or ARBs or acei
or ace-I or (ace adj2 inhibitor*) or “adren-
ergic beta antagonist*” or “adrenergic al-
pha antagonist*” or “beta block*” or “al-
pha block*” or diuretic* or “calcium chan-
nel blocker*” orCCBorCCBs or chloroth-
iazide or chlorthalidone or hydralazine or
hydrochlorothiazide or minoxidil or cap-
topril or enalapril or fosinopril or lisino-
pril or ramipril or losartan or irbesartan
or candesartan or eprosartan or valsartan
or olmesartan or telmisartan or amlodip-
ine or diltiazemor felodipine or nicardipine
or nifedipine or nimodipine or verapamil
or alprenolol or atenolol or metoprolol or
2113
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(Continued)
nadolol or oxprenolol or pindolol or pro-
pranolol or labetalol or prazosin or spirono-
lactone or triamterene or bumetanide or
furosemide or indapamide or frusemide or
diazoxide or eplerenone or amiloride or
clonidine or methyldopa or isradipine or
xipamide or barnidipine or lacidipine or
aranidipine or azelnidipine or benidipine
or clevidipine or darodipine or efonidipine
or manidipine or niguldipine or nilvadip-
ine or nisoldipine or nitrendipine or ox-
odipine or pranidipine or zofenopril or im-
idapril or cilazapril or azilsartan or fimasar-
tan or bisoprolol or acebutolol or celiprolol
or esmolol or sotalol or ketanserin or ura-
pidil or fentolamin or minoxidil or “mag-
nesium sulphate”).ti,ab
2. exp Hypertension/ or exp Antihyperten-
sive Drugs/
3. exp Adrenergic Drugs/
4. exp Diuretics/
5. exp Channel Blockers/
6. exp Hydralazine/
7. exp Captopril/
8. or/1-7
9. exp Drug Withdrawal/
10. withdraw*.ti,ab.
11. cessat*.ti,ab.
12. (reduce* or reducing* or reduct*).ti,ab.
13. taper*.ti,ab.
14. stop*.ti,ab.
15. (“carr* on” or continuation).ti,ab.
16. (“come off” or “taken off”).ti,ab.
17. or/9-16
18. 8 and 17
19. exp Clinical Trials/
20. randomly.ab.
21. randomi?ed.ti,ab.
22. placebo.ti,ab.
23. groups.ab.
24. “double-blind*”.ti,ab.
25. “single-blind*”.ti,ab.
26. RCT.ti,ab.
27. or/19-26
28. 18 and 27
5. CINAHL (EBSCOhost)
[searched 12 December 2015]
S1 TX antihypertensive* OR “anti-hyper-
tensive*” OR “angiotensin converting en-
zyme inhibitor*”
S2 TX “AT 2 receptor block*” OR “AT
150
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2 receptor antagon*” OR ARB OR ARBs
OR acei OR ace-I
S3 TX “adrenergic beta antagonist*” OR
“adrenergic alpha antagonist*” OR “beta
block*” OR “alpha block*” OR diuretic*
OR “calcium channel blocker*” OR CCB
OR CCBs
S4 TX chlorothiazide OR chlorthalidone
OR hydralazine OR hydrochlorothiazide
OR minoxidil OR captopril OR enalapril
OR fosinopril OR lisinopril OR ramipril
S5 TX losartan OR irbesartan OR can-
desartan OR eprosartan OR valsartan OR
olmesartan OR telmisartan OR amlodip-
ine OR diltiazem OR felodipine OR
nicardipine OR nifedipine OR nimodip-
ine OR verapamil OR alprenolol OR
atenolol OR metoprolol OR nadolol OR
oxprenolol
S6 TX pindolol OR propranolol OR
labetalol OR prazosin OR spironolac-
tone OR triamterene OR bumetanide
OR furosemide OR indapamide OR
frusemide OR diazoxide OR eplerenone
OR amiloride OR clonidine OR methyl-
dopa OR isradipine OR xipamide OR
barnidipine OR lacidipine OR aranidipine
OR azelnidipine
S7 TX benidipine OR clevidipine OR dar-
odipine OR efonidipine OR manidipine
OR niguldipine OR nilvadipine OR nisol-
dipine OR nitrendipine OR oxodipine OR
pranidipine OR zofenopril OR imidapril
OR cilazapril OR azilsartan OR fimasartan
OR bisoprolol OR acebutolol OR celipro-
lol OR esmolol OR sotalol OR ketanserin
OR urapidil OR fentolamin ORminoxidil
OR “magnesium sulphate”
S8 (MH “Hypertension”)
S9 (MH “Diuretics”)
S10 (MH “Angiotensin II Type I Recep-
tor Blockers”) OR (MH “Sodium Chan-
nel Blockers”) OR (MH “Calcium Chan-
nel Blockers”)
S11 (MH “Hydralazine”)
S12 (MH “Captopril”)
S13 TX withdraw*
S14 TX cessat*
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S15 TX reduce* OR reducing* OR reduct*
S16 TX taper*
S17 TX stop*
S18 TX “carr* on” OR continuation
S19 TX “come off” OR “taken off”
S20 S1 OR S2 OR S3 OR S4 OR S5 OR
S6 OR S7 OR S8 OR S9 OR S10 OR S11
OR S12
S21 S13ORS14OR S15ORS16OR S17
OR S18 OR S19
S22 S20 AND S21
S23 (MH “Randomized Controlled Tri-
als”)
S24 TX placebo
S25 AB groups
S26 AB randomly
S27 AB randomized control* trial
S28 TI randomized control* trial
S29 TX “double-blind*”
S30 TX “single-blind*”
S31 S23ORS24OR S25ORS26OR S27
OR S28 OR S29 OR S30
S32 S22 AND S31
S33 (MH “Cognition”) OR (MH “Cogni-
tion Disorders”) OR (MH “Delirium, De-
mentia, Amnestic, Cognitive Disorders”)
S34 TX cognit*
S35 TX memory
S36 TX “executive function*”
S37 TX dement*
S38 (MH “Dementia+”)
S39 S33ORS34OR S35ORS36OR S37
OR S38
S40 S32 AND S39
6. Web of Science core collection
[searched 12 December 2015]
TOPIC: (antihypertensive* or “anti-hy-
pertensive*” or “angiotensin converting en-
zyme inhibitor*” or “AT 2 receptor block*”
or “AT 2 receptor antagon*” or ARB
or ARBs or acei or ace-I or “adrenergic
beta antagonist*” or “adrenergic alpha an-
tagonist*” OR “beta block*” OR “alpha
block*” OR diuretic* OR “calcium chan-
nel blocker*” OR CCB OR CCBs OR
chlorothiazide OR chlorthalidone OR hy-
dralazine OR hydrochlorothiazide ORmi-
noxidil OR captopril OR enalapril OR
fosinopril OR lisinopril OR ramipril OR
losartan OR irbesartan OR candesartan
888
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OR eprosartan OR valsartan OR olmesar-
tan OR telmisartan OR amlodipine OR
diltiazem OR felodipine OR nicardipine
OR nifedipine OR nimodipine OR ver-
apamil OR alprenolol OR atenolol OR
metoprolol OR nadolol OR oxprenolol
OR pindolol OR propranolol OR labetalol
OR prazosin OR spironolactone OR tri-
amterene OR bumetanide OR furosemide
OR indapamide OR frusemide OR dia-
zoxide OR eplerenone OR amiloride OR
clonidine OR methyldopa OR isradipine
OR xipamide OR barnidipine OR lacidip-
ine OR aranidipine OR azelnidipine OR
benidipine OR clevidipine OR darodip-
ine OR efonidipine OR manidipine OR
niguldipine OR nilvadipine OR nisoldip-
ine OR nitrendipine OR oxodipine OR
pranidipine OR zofenopril OR imidapril
OR cilazapril OR azilsartan OR fimasartan
OR bisoprolol OR acebutolol OR celipro-
lol OR esmolol OR sotalol OR ketanserin
OR urapidil OR fentolamin ORminoxidil
OR “magnesium sulphate”) AND TOPIC:
(withdraw* or reduce or stop* or taper* or
cessat* or reduction) AND TOPIC: (cog-
nition or cognitive or “executive function*”
or memory or dementia or alzheimer*)
ANDTOPIC: (random* or trial or placebo
or “double-blind*” or “single-blind*” or
RCT or “control group*”)
Timespan: All years.
Search language=Auto
7. LILACS (BIREME)
[searched 12 December 2015]
“angiotensin con-
verting enzyme inhibitor$” OR antihyper-
tensive OR antihypertensives [Words] and
dementia OR demencia OR demência OR
alzheimer OR alzheimers OR alzheimer’s
OR cognition [Words]
10
8. CENTRAL (the Cochrane Library) (Is-
sue 1 of 4, 2015)
[searched 12 December 2015]
#1antihypertensive* or “anti-hyperten-
sive*” or “angiotensin converting enzyme
inhibitor*” or “AT 2 receptor block*” or
“AT 2 receptor antagon*” or ARB or ARBs
or acei or ace-I or “adrenergic beta antago-
nist*” or “adrenergic alpha antagonist*” or
“beta block*” or “alpha block*” or diuretic*
or “calcium channel blocker*” or CCB or
411
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CCBs or chlorothiazide or chlorthalidone
or hydralazine or hydrochlorothiazide or
minoxidil or captopril or enalapril or fos-
inopril or lisinopril or ramipril or losartan
or irbesartan or candesartan or eprosartan
or valsartan or olmesartan or telmisartan
or amlodipine or diltiazem or felodipine
or nicardipine or nifedipine or nimodipine
or verapamil or alprenolol or atenolol or
metoprolol or nadolol
#2metoprolol or nadolol or oxprenolol or
pindolol or propranolol or labetalol or pra-
zosin or spironolactone or triamterene or
bumetanide or furosemide or indapamide
or frusemide or diazoxide or eplerenone or
amiloride or clonidine or methyldopa or
isradipine or xipamide or barnidipine or
lacidipine or aranidipine or azelnidipine or
benidipine or clevidipine or darodipine or
efonidipine or manidipine or niguldipine
or nilvadipine or nisoldipine or nitrendip-
ine or oxodipine or pranidipine or zofeno-
pril or imidapril or cilazapril or azilsartan
or fimasartan or bisoprolol or acebutolol
or celiprolol or esmolol or sotalol or ke-
tanserin
#3urapidil or fentolamin or minoxidil or
“magnesium sulphate”
#4MeSH descriptor: [Antihypertensive
Agents] explode all trees
#5MeSH descriptor: [Hypertension] ex-
plode all trees
#6#1 or #2 or #3 or #4 or #5
#7reduc* or stop* or taper* or cessat* or
withdraw*
#8#6 and #7
#9cognit*
#10dement*
#11MeSH descriptor: [Cognition] explode
all trees
#12MeSH descriptor: [Dementia] explode
all trees
#13memory
#14“executive function*”
#15#9 or #10 or #11 or #12 or #13 or #14
#16#15 and #8
9. Clinicaltrials.gov (
www.clinicaltrials.gov)
[searched 12 December 2015]
Interventional studies:
(“angiotensin converting enzyme
inhibitor*” OR antihypertensive OR anti-
111
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hypertensives) AND (cognition OR cogni-
tive OR dementia)
Recruitment status: ALL
10. ICTRP Search Portal (apps.who.int/
trialsearch) [includes: Australian New
Zealand Clinical Trials Registry; Clinical-
Trilas.gov; ISRCTN;Chinese Clinical Trial
Registry; Clinical Trials Registry - India;
Clinical Research Information Service - Re-
public of Korea; German Clinical Trials
Register; Iranian Registry of Clinical Tri-
als; Japan Primary Registries Network; Pan
African Clinical Trial Registry; Sri Lanka
Clinical Trials Registry; The Netherlands
National Trial Register]
[searched 12 December 2015]
(“angiotensin converting enzyme
inhibitor” OR antihypertensive OR anti-
hypertensives) AND (cognition OR cogni-
tive OR dementia)
Recruitment status: ALL
4
TOTAL before de-duplication and first assess 13307
TOTAL after de-duplication 10985
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol, there was inconsistency in the description of the outcomes reported in ’Secondary outcomes’ and those to be reported
in our ’Summary of findings’ tables. We incorrectly stated we would look at recommencement of antihypertensive medications in
our ’Summary of findings’ table, when the outcome we intended to present in the table was adherence to withdrawal. This has been
amended.
In the protocol, we prespecified nine outcome measures for inclusion in the ’Summary of findings’ table. In accordance with Cochrane
guidance and following review by the Cochrane Dementia and Cognitive Improvement Group editorial team, we did not present
change in systolic and diastolic blood pressure and adherence to withdrawal in the table.
Due to a lack of data, we could not perform a meta-analysis on all outcomes we described in the protocol. In the protocol, we described
several sensitivity analyses, but these could not be performed with the two studies we included.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Antihypertensive Agents; ∗Withholding Treatment; Blood Pressure [physiology]; Cognition [drug effects]; Cognitive Dysfunction
[∗prevention & control]; Dementia [prevention & control]; Randomized Controlled Trials as Topic; Stroke; Time Factors
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MeSH check words
Adult; Humans
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